Skip to content
Evigrade

Acenocoumarol

AEMPS

Vitamin K antagonist anticoagulants

ATC code: B01AA07

Updated · Methodology

Indications

A

Mechanical heart valve

First line

Acenocoumarol is a vitamin K antagonist, and with a mechanical heart valve these drugs are the only oral anticoagulants that can be taken. The 2021 /EACTS guidelines prescribe them for life to every patient with a mechanical valve, and direct anticoagulants are contraindicated here. The reason is the RE-ALIGN trial (N Engl J Med 2013): in patients with mechanical valves dabigatran caused more thromboembolic events and more bleeding than warfarin, and the trial was stopped early. The Sintrom ficha técnica sets a target INR of 2.0 to 3.0 for an aortic prosthesis and 2.5 to 3.5 for a mitral or double prosthesis. The cardiologist chooses the exact target by valve type and the patient's risk factors. Missed doses and abrupt changes in diet risk valve thrombosis, so INR is checked regularly and any new medicine is agreed with whoever manages the anticoagulation.

ICD-10: Z95.2 · ICD-11: QB50.21

B

Atrial fibrillation

Second line

Acenocoumarol is a vitamin K antagonist anticoagulant, known in Spain as Sintrom. In atrial fibrillation it lowers the risk of stroke and embolism, with a target INR of 2.0 to 3.0 according to the AEMPS ficha técnica. The 2024 guidelines prefer direct oral anticoagulants for most patients: they cause fewer intracranial bleeds and need no INR monitoring. Vitamin K antagonists remain the choice with a mechanical valve and with moderate or severe mitral stenosis. In Spain the switch to a direct anticoagulant follows the 2016 AEMPS document: it is considered when, despite good adherence, INR stays in range less than 65 percent of the time by the Rosendaal method, or in less than 60 percent of measurements, over the last 6 months. While INR stays stable in range, acenocoumarol protects reliably, but it needs a blood test at least once a month and attention to every new medicine.

ICD-10: I48.9 · ICD-11: BC81.3

B

Venous thromboembolism

Second line

Acenocoumarol is a vitamin K antagonist. In deep vein thrombosis and pulmonary embolism it is used for treatment and to prevent recurrence, with a target INR of 2.0 to 3.0. According to the AEMPS ficha técnica it is started together with heparin: for at least 4 to 5 days and until two INR values fall in the target range at least 24 hours apart. The 2019 pulmonary embolism guidelines and CHEST 2021 prefer direct oral anticoagulants for most patients, since they need no INR-guided dosing. Acenocoumarol remains the choice where direct anticoagulants do not fit, above all in antiphospholipid syndrome: the ficha sets the same INR of 2.0 to 3.0 for it, and ESC 2019 does not recommend direct anticoagulants in this syndrome. Treatment length depends on the cause. After an episode with a clear temporary trigger 3 months is usually enough, and after unprovoked thrombosis treatment is often extended.

ICD-10: I82.9 · ICD-11: BD71

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

F

Primary cardiovascular disease prevention

Not recommended

Acenocoumarol (Sintrom) is an anticoagulant prescribed for atrial fibrillation, thrombosis and mechanical heart valves. It is sometimes seen as a way to «thin the blood» and prevent heart attack or stroke in people who have no atrial fibrillation, thrombosis or valve prosthesis. For that kind of prevention the drug does not work: an anticoagulant only protects where there is a source of clots. The 2021 guidelines on cardiovascular disease prevention include no anticoagulants for such people. The WARCEF trial (N Engl J Med 2012) tested a vitamin K antagonist even in higher-risk patients with heart failure and sinus rhythm. On the combined count of strokes, brain hemorrhages and deaths there was no difference from aspirin, 7.47 versus 7.93 events per 100 patient-years, while major bleeding on warfarin was twice as common, 1.78 versus 0.87. If acenocoumarol was offered «for prevention» or to «thin the blood» without atrial fibrillation, thrombosis or a valve prosthesis, consider seeking a second opinion.

How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

A coumarin anticoagulant and vitamin K antagonist. Acenocoumarol blocks VKORC1, the enzyme that returns vitamin K to its active form. Without it the liver releases incomplete clotting factors II, VII, IX and X, along with proteins C and S, and blood clots more slowly. The effect is tracked by INR: it rises 36 to 72 hours after the first doses and returns to normal within a few days of stopping. Absorption is rapid, peak plasma levels come at 1 to 3 hours and 98.7 percent of the drug is bound to plasma proteins. The liver breaks it down mainly through CYP2C9, and CYP1A2 and CYP2C19 also clear the R-enantiomer. The half-life is 8 to 11 hours, much shorter than that of warfarin.

Safety

Contraindications

  • Hypersensitivity to acenocoumarol or other coumarin derivatives
  • Pregnancy
  • Patients unable to follow treatment and INR monitoring without supervision
  • Bleeding tendency, clotting disorders, platelets below 50×10⁹/L
  • Recent or planned surgery on the central nervous system or eyes, extensive traumatic procedures
  • Peptic ulcer, bleeding from the gastrointestinal, urogenital or respiratory tract, intracranial hemorrhage
  • Acute pericarditis, pericardial effusion, infective endocarditis
  • Severe hypertension
  • Severe hepatic impairment
  • Severe renal impairment when bleeding risk outweighs thrombotic risk
  • Increased fibrinolytic activity, for example after lung, prostate or uterine surgery

Serious adverse effects

  • Severe bleeding, including gastrointestinal and intracranial, up to hemorrhagic shock
  • Hemorrhagic skin necrosis, usually with protein C or S deficiency
  • Calciphylaxis
  • Acute kidney injury with excessive anticoagulation and hematuria
  • Liver injury
  • Vasculitis
  • Anemia from bleeding

Common adverse effects

  • Bleeding at various sites

Pregnancy: can you take Acenocoumarol?

Contraindicated in pregnancy. Like other coumarin derivatives, acenocoumarol crosses the placenta and may cause birth defects (AEMPS ficha técnica, sections 4.3 and 4.6). Women of childbearing potential need effective contraception during treatment. If pregnancy is planned, the anticoagulant is changed in advance together with the doctor who manages the anticoagulation.

Breastfeeding: can you take Acenocoumarol?

Acenocoumarol passes into breast milk in very small amounts that, from the limited data available, do not harm the baby (AEMPS ficha técnica, section 4.6). The decision to breastfeed is made individually, and the baby's clotting and vitamin K are sometimes checked first. The ficha advises giving the baby 1 mg of vitamin K1 a week as prevention and keeping the mother's INR within the target range.

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Renal dose adjustment for all the patient's drugs

Enter the patient's kidney function and drugs. On one page you'll see the dose each label gives

Acenocoumarol label on CIMA (AEMPS, in Spanish) →

Drug–drug interactions

55 pairs found. Sorted from critical to minor.

CriticalEdoxabanDirect oral anticoagulants (factor Xa inhibitors)

Mechanism

Edoxaban directly and reversibly inhibits clotting factor Xa and so reduces thrombin generation (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Acenocoumarol is a coumarin derivative and a vitamin K antagonist. It reduces the gamma-carboxylation of clotting factors II, VII, IX and X, and its effect lasts a little over 24 hours (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Edoxaban is contraindicated with any other anticoagulant, oral ones included, because of the increased risk of bleeding (EMA). Acenocoumarol is not named in this contraindication, but its own SmPC places it among the oral anticoagulants of the vitamin K antagonist group (AEMPS). Edoxaban itself prolongs the prothrombin time and the international normalised ratio (INR). With a vitamin K antagonist, it can raise the INR after an edoxaban dose by up to 46% (EMA).

Symptoms

Edoxaban increases the risk of bleeding, which can be severe or even fatal and can occur at any site (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). Acenocoumarol can also cause severe bleeding, up to haemorrhagic and hypovolaemic shock, or fatal bleeding. Concomitant treatment is one of the risk factors for such bleeding (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If haemoglobin or blood pressure falls without explanation, look for a bleeding site (EMA).

Management

Edoxaban is contraindicated with any other anticoagulant, oral ones included, except when switching from one oral anticoagulant to another (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The US label does not recommend long-term use of edoxaban with other anticoagulants (edoxaban label, US Food and Drug Administration, ). The switching rules in the edoxaban SmPC cover vitamin K antagonists as a group. When switching from acenocoumarol, stop it and start edoxaban once the international normalised ratio (INR) is 2.5 or lower (EMA). When switching from edoxaban to acenocoumarol, keep anticoagulation continuous. With the oral option, patients on 60 mg take edoxaban 30 mg once daily together with a suitable dose of the vitamin K antagonist. Patients on 30 mg (creatinine clearance 15–50 mL/min, body weight 60 kg or less, or certain P-glycoprotein inhibitors) take 15 mg once daily (EMA). Do not give a loading dose of the vitamin K antagonist (EMA). The acenocoumarol SmPC also advises starting acenocoumarol without a loading dose (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). During the first 14 days of co-administration, the edoxaban SmPC recommends measuring the INR at least three times, just before the daily edoxaban dose. Stop edoxaban once the INR reaches 2.0. After 14 days, the SmPC recommends stopping edoxaban and continuing to adjust the vitamin K antagonist dose to an INR of 2–3 (EMA). With the parenteral option, stop edoxaban and start a parenteral anticoagulant and the vitamin K antagonist at the time of the next scheduled edoxaban dose. Stop the parenteral anticoagulant once the INR is stable at 2.0 or higher (EMA). If severe bleeding occurs, stop edoxaban. There is no specific antidote, and vitamin K is not expected to affect edoxaban activity (EMA).

Pair details →Edoxaban →

CriticalHypericum perforatumAntidepressants. Other antidepressants of herbal origin

Mechanism

St John's wort (Hypericum) preparations induce CYP3A4, CYP2B6, CYP2C9, CYP2C19 and P-glycoprotein, and hyperforin does this dose-dependently. Other drugs may then be eliminated faster, and their plasma levels fall (St John's wort monograph, European Medicines Agency, ). Liver enzymes, mainly CYP2C9, metabolise acenocoumarol, and inducers of CYP2C9, CYP2C19 and CYP3A4 can reduce its anticoagulant effect (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish SmPC of a St John's wort product names acenocoumarol together with warfarin. For both, plasma levels fall, the anticoagulant effect weakens and there is a risk of treatment failure. The anticoagulant dose has to be increased (St John's wort SmPC, AEMPS). The SmPC of a generic acenocoumarol adds that the interaction has been described with warfarin and phenprocoumon and cannot be excluded for acenocoumarol (generic acenocoumarol SmPC, AEMPS).

Symptoms

Acenocoumarol plasma levels fall, its anticoagulant effect weakens, and there is a risk of treatment failure (St John's wort summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The international normalised ratio (INR) then falls below the target range, and protection against clots, the reason for acenocoumarol treatment, weakens. After St John's wort is stopped, the raised enzyme activity returns to normal within a week (St John's wort monograph, European Medicines Agency, ). The effect of acenocoumarol can then increase again, especially if its dose was raised. With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).

Management

The combination is contraindicated. The St John's wort monograph of the European Medicines Agency () contraindicates St John's wort with coumarin-type anticoagulants, which include acenocoumarol. For well-established use products it applies without conditions, and for traditional use products it applies when the daily hyperforin dose exceeds 1 mg (St John's wort monograph, EMA, sections 4.3 and 4.5). The Spanish summary of product characteristics (SmPC) of a St John's wort product also contraindicates coumarin-type anticoagulants. Its interaction table lists acenocoumarol with warfarin among the drugs that must not be taken with St John's wort (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). The authorisation of that product has been suspended since 11 June 2026, and there is no other current Spanish St John's wort SmPC. For traditional use products with a daily hyperforin intake of up to 1 mg, taken for no longer than 2 weeks, the monograph reports no clinically relevant interactions. This applies to drugs metabolised via CYP1A2, CYP2B6, CYP2C9, CYP2C19 or CYP3A4 or transported by P-glycoprotein (St John's wort monograph, EMA, section 4.5). The acenocoumarol SmPCs are less strict. They list St John's wort among drugs that need close and frequent coagulation checks, for example twice a week, both when they are added and when they are stopped (acenocoumarol SmPCs, AEMPS). If St John's wort has already been taken with acenocoumarol, check coagulation just as often after it is stopped (acenocoumarol SmPCs, AEMPS). The raised enzyme activity returns to normal within a week (St John's wort monograph, EMA). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Hypericum perforatum →

MajorAcetylsalicylic acidAntiplatelet agents (low dose) / NSAIDs (analgesic dose)

Mechanism

Acenocoumarol, like other coumarins, acts through vitamin K, which the liver needs for gamma-carboxylation of the prothrombin complex factors (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acetylsalicylic acid irreversibly inhibits platelet aggregation, and the effect lasts for several days after a dose (acetylsalicylic acid 100 mg SmPC, AEMPS). The two drugs act on different parts of haemostasis, so the combination raises the risk of bleeding, including gastrointestinal bleeding (acenocoumarol SmPCs, AEMPS). Salicylates also displace oral anticoagulants from plasma protein binding sites (acetylsalicylic acid 500 mg SmPC, AEMPS) and can themselves cause bleeding, ulceration and perforation of the upper digestive tract (acetylsalicylic acid 100 mg SmPC, AEMPS). The US label for extended-release acetylsalicylic acid lists anticoagulants among the risk factors for bleeding (US Food and Drug Administration, ).

Symptoms

The main risk is bleeding, including from the stomach and intestine, and it can start without earlier warning symptoms (acenocoumarol and acetylsalicylic acid 100 mg summaries of product characteristics, SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). Signs of gastric bleeding are black tarry stools, vomiting blood, low blood pressure, cold sweat, abdominal pain and dizziness (acetylsalicylic acid 100 mg SmPC, AEMPS). Bleeding is the main sign of an excessive acenocoumarol effect. The most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding and bleeding into the joints (acenocoumarol SmPC, overdose section, AEMPS).

Management

The acenocoumarol summary of product characteristics (SmPC) generally advises against combining acenocoumarol with acetylsalicylic acid and other salicylates unless this is strictly indicated, for example when an oral anticoagulant and an antiplatelet drug are both needed (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Give analgesic doses (500 mg tablets, no more than 4000 mg a day) with coumarins only when there is no other treatment option (acetylsalicylic acid 500 mg SmPC, AEMPS). Avoid antiplatelet doses (100–300 mg a day for secondary prevention) with anticoagulants whenever possible. If the combination cannot be avoided, monitor the international normalised ratio (INR) carefully (acetylsalicylic acid 100 mg SmPC, AEMPS). The SmPC of one generic acetylsalicylic acid 100 mg product lists use with coumarins as a contraindication, although other sections of the same document only advise against it. The originator product of the same form has no such contraindication (AEMPS). When the drugs are given together, use close and frequent coagulation checks, for example twice a week, including after acetylsalicylic acid is stopped (acenocoumarol SmPC, AEMPS). Explain the signs of gastric bleeding to the patient (black stools, vomiting blood, low blood pressure, cold sweat, abdominal pain, dizziness): if they appear, stop acetylsalicylic acid at once (acetylsalicylic acid 100 mg SmPC, AEMPS). For significant bleeding, stop acenocoumarol and give vitamin K1 5–10 mg intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, overdose section, AEMPS).

Pair details →Acetylsalicylic acid →

MajorAlpha-tocopherolFat-soluble vitamin E

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The originator acenocoumarol SmPC lists vitamin E (alpha-tocopherol) among drugs that potentiate the anticoagulant effect or can impair haemostasis and increase the risk of bleeding (AEMPS). According to the vitamin E SmPC, high doses of 300 mg a day or more given with oral anticoagulants can prolong the prothrombin time. In people taking vitamin K antagonists, alpha-tocopheryl acetate has been reported to change the INR and prothrombin time, which can increase the risk of bleeding (vitamin E SmPC, AEMPS). Excess vitamin E can antagonise vitamin K and inhibit prothrombin production (AEMPS).

Symptoms

The main risk is bleeding. According to the vitamin E summary of product characteristics (SmPC), alpha-tocopheryl acetate can increase the risk of bleeding in people taking vitamin K antagonists. The adverse effects of vitamin E itself include an increased bleeding tendency with long-term doses above 800 IU a day. Gum bleeding can also occur, rarely, with long-term doses above 400–800 IU a day (vitamin E SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints (AEMPS).

Management

The originator acenocoumarol summary of product characteristics (SmPC) lists vitamin E among drugs whose combination with acenocoumarol is generally not recommended unless strictly indicated. If the drugs are still given together, check coagulation more often (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). This SmPC sets no vitamin E dose threshold. The generic acenocoumarol SmPC places vitamin E in a milder list, among drugs that can potentiate the anticoagulant and that prescribers should take into account (AEMPS). According to the vitamin E SmPC, high doses of 300 mg a day or more can prolong the prothrombin time (vitamin E SmPC, AEMPS). Use caution when combining vitamin E with vitamin K antagonists: the anticoagulant dose may need adjusting, or vitamin E treatment may need to be reconsidered. Apart from specific disorders, generally avoid vitamin E doses of 400 IU a day or more (vitamin E SmPC, AEMPS). When the two drugs are given together, the acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both after vitamin E is started and after it is stopped. Adjust the acenocoumarol dose by the prothrombin time and the international normalised ratio (INR) (acenocoumarol SmPCs, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Alpha-tocopherol →

MajorAmiodaroneClass III antiarrhythmics (Vaughan Williams)

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist, and in the liver CYP2C9 is the main enzyme that metabolises it (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Amiodarone and its metabolite desethylamiodarone inhibit CYP1A1, CYP1A2, CYP2C9, CYP2D6 and CYP3A4. According to the Spanish amiodarone SmPCs, amiodarone raises the levels of coumarin oral anticoagulants and can potentiate their effect (amiodarone SmPCs, AEMPS). The acenocoumarol SmPCs, both the originator and a generic, also list amiodarone among drugs that can potentiate its anticoagulant effect (acenocoumarol SmPCs, AEMPS). For warfarin, the US amiodarone label reports a 100% rise in prothrombin time after 3–4 days of combined use (amiodarone prescribing information, US Food and Drug Administration, ). The documents give no such figures for acenocoumarol.

Symptoms

According to the Spanish amiodarone SmPCs, combining amiodarone with oral anticoagulants can increase the risk of bleeding. Amiodarone interactions can still appear for several months after it is stopped (amiodarone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). For warfarin, the US amiodarone label warns of serious or fatal bleeding (amiodarone prescribing information, US Food and Drug Administration, ). Acenocoumarol can cause serious or fatal bleeding, including haemorrhagic shock. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints, as well as fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain (acenocoumarol SmPC, AEMPS).

Management

The combination is not contraindicated, but with amiodarone the acenocoumarol dose needs review and coagulation needs more frequent checks. According to the Spanish amiodarone SmPCs, check the prothrombin time and the international normalised ratio (INR) more often than usual and adjust the oral anticoagulant dose during and after amiodarone treatment (amiodarone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The generic amiodarone SmPC states that the coumarin dose should be reduced accordingly (amiodarone SmPC, AEMPS). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week, both when amiodarone is added and when it is stopped (acenocoumarol SmPCs, AEMPS). Amiodarone interactions can persist for several months after it is stopped, so INR checks and acenocoumarol dose adjustment continue after the end of the course (amiodarone SmPC, AEMPS; amiodarone prescribing information, US Food and Drug Administration, ). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days (acenocoumarol SmPC, AEMPS). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt it and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Amiodarone →

MajorCelecoxibSelective COX-2 inhibitor (coxib)

Mechanism

The Spanish acenocoumarol SmPCs, both the originator and a generic, name celecoxib explicitly among the non-steroidal anti-inflammatory drugs (NSAIDs), including cyclo-oxygenase-2 (COX-2) inhibitors, that potentiate the anticoagulant effect of acenocoumarol or impair haemostasis. These drugs raise the risk of bleeding, including gastrointestinal bleeding (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Celecoxib itself, like other NSAIDs, can cause ulcers, perforations and bleeding in the stomach and bowel. With anticoagulants, the risk of bleeding may rise (celecoxib SmPC, AEMPS). According to the US label, celecoxib and anticoagulants such as warfarin have a synergistic effect on bleeding. The risk of serious bleeding is higher with the combination than with either drug alone (celecoxib prescribing information, US Food and Drug Administration, ). A rise in the prothrombin time has been reported with celecoxib and warfarin, but the documents give no data for acenocoumarol (AEMPS). In vitro, celecoxib did not inhibit CYP2C9 (FDA), the main enzyme that metabolises acenocoumarol (acenocoumarol SmPC, AEMPS).

Symptoms

The main risk is bleeding, above all from the stomach and bowel. Celecoxib can cause ulcers, perforations and bleeding in the upper and lower digestive tract, sometimes fatal. With celecoxib plus warfarin, serious bleeding with a raised prothrombin time has been reported, some of it fatal, mostly in older people (celecoxib summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older, with a history of gastrointestinal bleeding and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds and bleeding gums (acenocoumarol SmPC, AEMPS).

Management

The Spanish acenocoumarol SmPCs, both the originator and a generic, name celecoxib explicitly among the non-steroidal anti-inflammatory drugs (NSAIDs), including cyclo-oxygenase-2 (COX-2) inhibitors. They generally do not recommend combining these drugs with acenocoumarol unless the combination is strictly indicated (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If the combination cannot be avoided, use close and frequent coagulation checks, for example twice a week, both after celecoxib is started and after it is stopped. While the two drugs are taken together, test coagulation more often than usual (acenocoumarol SmPCs, AEMPS). Monitor the international normalised ratio (INR) especially carefully in the first days of celecoxib and when its dose is changed (celecoxib SmPC, AEMPS). Watch for signs of bleeding (celecoxib prescribing information, US Food and Drug Administration, ). Use the lowest effective daily dose of celecoxib for the shortest possible time (celecoxib SmPC, AEMPS). Gastrointestinal complications with celecoxib are more likely in older people, with a history of ulcer or bleeding, with other NSAIDs, acetylsalicylic acid or glucocorticoids, and with alcohol use (celecoxib SmPC, AEMPS). Peptic ulcer and gastrointestinal bleeding are contraindications to acenocoumarol, and active peptic ulcer and gastrointestinal bleeding are contraindications to celecoxib (acenocoumarol and celecoxib SmPCs, AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Celecoxib →

MajorClopidogrelAntiplatelet agents – P2Y12 receptor inhibitors

Mechanism

Clopidogrel inhibits platelet aggregation (clopidogrel summary of product characteristics, SmPC, European Medicines Agency, ), while acenocoumarol acts through vitamin K, which the liver needs for gamma-carboxylation of the prothrombin complex factors (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). These effects on haemostasis are independent and add up, so bleeding with the combination can be more severe (EMA). Pharmacokinetic data exist only for warfarin. In people on long-term warfarin, clopidogrel 75 mg a day did not change the pharmacokinetics of S-warfarin or the international normalised ratio (INR), but the risk of bleeding increased (EMA; clopidogrel label, US Food and Drug Administration, ). Clopidogrel inhibits platelets for their whole lifespan, 7–10 days (FDA).

Symptoms

The main risk is bleeding. On clopidogrel, bruising happens more easily and bleeding takes longer than usual to stop (clopidogrel label, US Food and Drug Administration, ). Bleeding with clopidogrel was reported mainly in the first month of treatment and included intracranial bleeding, in some cases fatal (clopidogrel summary of product characteristics, SmPC, European Medicines Agency, ). Warning signs are unexpected or prolonged bleeding, pink, red or brown urine, and red or black tarry stools (FDA). Bleeding is the main sign of an excessive acenocoumarol effect. The most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding and bleeding into the joints (acenocoumarol SmPC, overdose section, Spanish Agency of Medicines and Medical Devices, AEMPS).

Management

Clopidogrel is not recommended with oral anticoagulants because bleeding may become more severe (clopidogrel summary of product characteristics, SmPC, European Medicines Agency, ). The acenocoumarol SmPC also generally advises against the combination unless it is strictly indicated, for example when an oral anticoagulant and an antiplatelet drug are both needed (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If the drugs are given together, use close and frequent coagulation checks with the international normalised ratio (INR), for example twice a week, including after clopidogrel is stopped (AEMPS). Watch carefully for signs of bleeding, including occult bleeding, especially in the first weeks of treatment and after cardiac or other surgery. If clinical signs of bleeding appear, promptly consider a full blood count and other appropriate tests (EMA). If the antiplatelet effect is temporarily not wanted before elective surgery, stop clopidogrel 7 days beforehand (EMA). Stopping clopidogrel increases the risk of cardiovascular events. After a necessary interruption, for example because of bleeding, restart it as soon as possible once the bleeding has stopped (clopidogrel label, US Food and Drug Administration, ). For significant bleeding, stop acenocoumarol and give vitamin K1 5–10 mg intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, overdose section, AEMPS).

Pair details →Clopidogrel →

MajorDexketoprofenNon-steroidal anti-inflammatory drugs, propionic acid derivatives

Mechanism

Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the effects of coumarin-type anticoagulants for three reasons: dexketoprofen is highly bound to plasma proteins, inhibits platelet function and damages the gastroduodenal mucosa (dexketoprofen summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dexketoprofen is 99% bound to plasma proteins, and as a non-selective NSAID it inhibits prostaglandin synthesis, inhibits platelet aggregation and prolongs bleeding time (AEMPS). Acenocoumarol acts through vitamin K, which the liver needs for gamma-carboxylation of the prothrombin complex factors. With NSAIDs, the risk of bleeding on acenocoumarol rises, including gastrointestinal bleeding (acenocoumarol SmPCs, AEMPS).

Symptoms

The main risk is bleeding, above all from the stomach and intestine. With non-steroidal anti-inflammatory drugs (NSAIDs), gastrointestinal bleeding, ulceration and perforation can occur at any time during treatment, with or without warning symptoms, and can be fatal (dexketoprofen summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The risk is higher with high doses, in older people and in people with a history of ulcer, especially if it was complicated by bleeding or perforation (AEMPS). Bleeding is the main sign of an excessive acenocoumarol effect. The most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, vomiting blood, gastrointestinal, uterine, nose and gum bleeding and bleeding into the joints (acenocoumarol SmPC, overdose section, AEMPS).

Management

Both summaries of product characteristics (SmPCs) advise against the combination. The acenocoumarol SmPC advises against NSAIDs unless the combination is strictly indicated (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The dexketoprofen SmPC advises against combining dexketoprofen with warfarin, other coumarins and heparins (dexketoprofen SmPC, AEMPS). If the combination cannot be avoided, strict clinical control and laboratory monitoring are needed (dexketoprofen SmPC, AEMPS). Use close and frequent coagulation checks with the international normalised ratio (INR), for example twice a week, including after dexketoprofen is stopped (acenocoumarol SmPC, AEMPS). Dexketoprofen is not intended for long-term use. Limit treatment to the period of symptoms, do not exceed 75 mg a day, and start older people on 50 mg a day (dexketoprofen SmPC, AEMPS). Giving the lowest effective dose for the shortest time can reduce adverse reactions (AEMPS). Consider gastric protection with misoprostol or a proton pump inhibitor in people with a history of gastrointestinal disease and in people taking other drugs that raise the gastrointestinal risk. Stop dexketoprofen if gastrointestinal bleeding or ulceration occurs (AEMPS). For significant bleeding, stop acenocoumarol and give vitamin K1 5–10 mg intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, overdose section, AEMPS).

Pair details →Dexketoprofen →

MajorDiclofenacNon-steroidal anti-inflammatory drugs (NSAIDs)

Mechanism

The Spanish acenocoumarol SmPCs, both the originator and a generic, list non-steroidal anti-inflammatory drugs (NSAIDs) among drugs that potentiate the anticoagulant effect of acenocoumarol or impair haemostasis. These drugs raise the risk of bleeding, including gastrointestinal bleeding (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The diclofenac SmPC classes diclofenac as an NSAID. Diclofenac inhibits prostaglandin synthesis and can itself cause ulcers, perforations and bleeding in the stomach and bowel (diclofenac SmPC, AEMPS). Clinical studies do not appear to show that diclofenac changes the action of anticoagulants, but there are reports of a higher risk of bleeding when the two are taken together (diclofenac SmPC, AEMPS). According to the US label, diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The risk of serious bleeding is higher with the combination than with either drug alone (diclofenac prescribing information, US Food and Drug Administration, ).

Symptoms

The main risk is bleeding, above all from the stomach and bowel. With non-steroidal anti-inflammatory drugs, including diclofenac, gastrointestinal bleeding, ulcers and perforations can occur at any time during treatment, sometimes fatally, with or without warning symptoms. The risk is higher in older people and rises with the dose (diclofenac summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older, with a history of gastrointestinal bleeding and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds and bleeding gums (acenocoumarol SmPC, AEMPS).

Management

The Spanish acenocoumarol SmPCs, both the originator and a generic, generally do not recommend combining acenocoumarol with non-steroidal anti-inflammatory drugs (NSAIDs) unless the combination is strictly indicated (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The diclofenac SmPC classes diclofenac as an NSAID (diclofenac SmPC, AEMPS). If the combination cannot be avoided, use close and frequent coagulation checks, for example twice a week, both after diclofenac is started and after it is stopped. While the two drugs are taken together, test the international normalised ratio (INR) more often than usual (acenocoumarol SmPCs, AEMPS). Use diclofenac with special caution and careful monitoring with coumarin-type oral anticoagulants (diclofenac SmPC, AEMPS), and watch for signs of bleeding (diclofenac prescribing information, US Food and Drug Administration, ). Use the lowest effective dose of diclofenac for the shortest possible time, and start older people on the lowest effective dose (diclofenac SmPC, AEMPS). With other drugs that raise gastrointestinal risk, consider a protective agent such as misoprostol or a proton pump inhibitor (diclofenac SmPC, AEMPS). Proton pump inhibitors such as omeprazole, however, may themselves potentiate acenocoumarol (acenocoumarol SmPCs, AEMPS). Stop diclofenac at once if gastrointestinal bleeding or an ulcer occurs (diclofenac SmPC, AEMPS). Peptic ulcer and gastrointestinal bleeding are contraindications to acenocoumarol, and active gastrointestinal ulcer, bleeding or perforation are contraindications to diclofenac (acenocoumarol and diclofenac SmPCs, AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Diclofenac →

MajorIbuprofenNon-steroidal anti-inflammatory drugs (NSAIDs)

Mechanism

Ibuprofen, like other non-steroidal anti-inflammatory drugs (NSAIDs), reversibly inhibits platelet aggregation and function and prolongs bleeding time (ibuprofen summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). NSAIDs may increase the effects of coumarin-type anticoagulants, and ibuprofen itself can cause gastrointestinal bleeding, ulceration and perforation (AEMPS). Acenocoumarol acts through vitamin K, which the liver needs for gamma-carboxylation of the prothrombin complex factors. With NSAIDs, the risk of bleeding on acenocoumarol rises, including gastrointestinal bleeding (acenocoumarol SmPCs, AEMPS). In short-term controlled studies ibuprofen did not significantly change prothrombin time in people taking coumarin-type anticoagulants, but bleeding has been reported with this combination (ibuprofen label, US Food and Drug Administration, ). In data for warfarin, warfarin and NSAIDs have a synergistic effect on the risk of serious gastrointestinal bleeding. The risk with both is higher than with either drug alone (FDA).

Symptoms

The main risk is bleeding, above all from the stomach and intestine. With non-steroidal anti-inflammatory drugs (NSAIDs), gastrointestinal bleeding, ulceration and perforation can occur at any time during treatment, with or without warning symptoms, and can be fatal (ibuprofen summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The risk is higher with increasing doses, in older people and in people with a history of ulcer, especially if it was complicated by bleeding or perforation (AEMPS). Bleeding is the main sign of an excessive acenocoumarol effect. The most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, vomiting blood, gastrointestinal, uterine, nose and gum bleeding and bleeding into the joints (acenocoumarol SmPC, overdose section, AEMPS).

Management

The acenocoumarol summary of product characteristics (SmPC) generally advises against combining acenocoumarol with non-steroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, unless this is strictly indicated (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If the drugs are given together, use close and frequent coagulation checks with the international normalised ratio (INR), for example twice a week, including after ibuprofen is stopped (AEMPS). Use ibuprofen with particular caution with coumarin-type oral anticoagulants (ibuprofen SmPC, AEMPS), and monitor people taking anticoagulants carefully during ibuprofen treatment (ibuprofen label, US Food and Drug Administration, ). Giving the lowest effective dose of ibuprofen for the shortest time can reduce adverse reactions (AEMPS). In older people and people with a history of ulcer, start with the lowest dose. For them, the ibuprofen SmPC recommends gastric protection with misoprostol or a proton pump inhibitor. Consider such protection in people taking other drugs that raise the gastrointestinal risk (AEMPS). If gastrointestinal bleeding or ulceration occurs, stop ibuprofen at once (AEMPS). For significant bleeding, stop acenocoumarol and give vitamin K1 5–10 mg intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, overdose section, AEMPS).

Pair details →Ibuprofen →

MajorMetamizole sodiumAnalgesics and antipyretics. Pyrazolones

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist. Its interactions with other drugs act through absorption, through liver enzymes, mainly CYP2C9, and through the availability of vitamin K needed to activate clotting factors (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs, both the originator and a generic, list phenylbutazone and other pyrazolone derivatives among drugs that potentiate the anticoagulant effect or impair haemostasis and raise the risk of bleeding (acenocoumarol SmPCs, AEMPS). The metamizole SmPC classes metamizole as a pyrazolone. It states that pyrazolones may interact with oral anticoagulants, but it is not known to what extent this applies to metamizole itself (metamizole SmPC, AEMPS). Metamizole can also induce the enzymes CYP2B6 and CYP3A4 (metamizole SmPC, AEMPS), and CYP3A4 inducers may reduce the effect of acenocoumarol (acenocoumarol SmPCs, AEMPS). The documents do not say how large this effect is for this combination.

Symptoms

The main risk is bleeding. Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older, with a history of gastrointestinal bleeding and with concomitant treatment (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Gastrointestinal bleeding has been reported with metamizole. Many of these patients were also taking other drugs linked to such bleeding, for example non-steroidal anti-inflammatory drugs, or had taken an overdose of metamizole (metamizole SmPC, AEMPS). With metamizole, bruising, bleeding and pallor together with fever, sore throat and painful changes in the lining of the mouth or nose may signal a blood disorder. Agranulocytosis and thrombocytopenia occur very rarely (metamizole SmPC, AEMPS).

Management

The Spanish acenocoumarol SmPCs, both the originator and a generic, generally do not recommend combining acenocoumarol with pyrazolone derivatives unless the combination is strictly indicated (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The metamizole SmPC classes metamizole as a pyrazolone (metamizole SmPC, AEMPS). It adds that it is not known to what extent the interaction of pyrazolones with oral anticoagulants applies to metamizole itself (AEMPS). The acenocoumarol SmPCs make no such reservation (AEMPS). If metamizole cannot be avoided, use close and frequent coagulation checks, for example twice a week, both after metamizole is started and after it is stopped. While the two drugs are taken together, test the international normalised ratio (INR) more often than usual (acenocoumarol SmPCs, AEMPS). If bruising, bleeding, pallor, fever, sore throat or painful changes in the lining of the mouth appear, stop metamizole at once without waiting for laboratory results. Monitor the full blood count with differential until it returns to normal (metamizole SmPC, AEMPS). In older people and in renal or hepatic impairment, use metamizole only after weighing benefit and risk (metamizole SmPC, AEMPS). Use acenocoumarol with caution in mild to moderate renal or hepatic impairment (acenocoumarol SmPC, AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Metamizole sodium →

MajorPhytomenadioneVitamin K1, haemostatic, antidote for coumarin anticoagulant overdose

Mechanism

Acenocoumarol inhibits the hepatic gamma-carboxylation of vitamin K-dependent clotting factors (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Vitamin K1 (phytomenadione) is needed to make factors II, VII, IX and X, and the phytomenadione SmPC explicitly names it as an antagonist of coumarin derivatives, including acenocoumarol (phytomenadione SmPC, AEMPS). Vitamin K1 is therefore the antidote to acenocoumarol. It can reverse the effect of acenocoumarol on clotting factors within 3–5 hours (acenocoumarol SmPC, AEMPS). Vitamin K1 starts to act 1–3 hours after an intravenous dose and 4–6 hours after an oral dose (phytomenadione SmPC, AEMPS). The same mechanism can make it harder to restore anticoagulation later. Vitamin K1 doses above 5 mg can cause resistance to further anticoagulant treatment for several days (generic acenocoumarol SmPC, AEMPS). After an intramuscular injection, the muscle keeps releasing vitamin K1 gradually, like a depot (phytomenadione SmPC, AEMPS). Foods rich in vitamin K, such as spinach, cauliflower and cabbage, can also weaken the effect of acenocoumarol (acenocoumarol SmPC, AEMPS).

Symptoms

The main risk is loss of the anticoagulant effect of acenocoumarol. The US vitamin K1 label warns that after correction of excessive anticoagulation, a patient who still needs anticoagulant therapy again faces the clotting hazards that existed before. An excessive vitamin K1 dose can also restore the conditions that allowed thromboembolism (vitamin K1 prescribing information, US Food and Drug Administration, ). Intramuscular injections in patients on anticoagulant treatment carry a risk of haematomas (phytomenadione summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). After intravenous use, anaphylactoid reactions and vein irritation or phlebitis are very rare (phytomenadione SmPC, AEMPS). The US label reports severe and fatal hypersensitivity reactions, including anaphylaxis, with intravenous and intramuscular use (FDA).

Management

Phytomenadione 10 mg/mL must not be given intramuscularly to patients on anticoagulant treatment. In muscle it acts as a depot, makes it harder to return to anticoagulation and carries a risk of haematomas (phytomenadione summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Avoid intramuscular injections throughout acenocoumarol treatment (acenocoumarol SmPC, AEMPS). Choose the antidote dose of vitamin K1 according to the international normalised ratio (INR) and bleeding. According to the acenocoumarol SmPC, with an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth. In significant bleeding, give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS). For acenocoumarol, the phytomenadione SmPC gives 1–2 mg by mouth or intravenously at an INR of 5–8 without symptoms or with mild bleeding. At an INR above 8, it gives 3–5 mg by mouth or 1–2 mg intravenously. In severe bleeding, it gives 5 mg intravenously together with fresh frozen plasma, prothrombin complex concentrate or prothrombin and factor VII concentrates (phytomenadione SmPC, AEMPS). Older patients are more sensitive to reversal with vitamin K1, so give them doses at the lower end of the ranges. In severe liver disease, monitor the INR carefully after vitamin K1 (phytomenadione SmPC, AEMPS). The US label asks for the lowest possible vitamin K1 dose and regular INR checks (vitamin K1 prescribing information, US Food and Drug Administration, ). If anticoagulation is needed after vitamin K1 doses above 5 mg, heparin can be used temporarily, with acenocoumarol restarted at the same time. Stop heparin once the INR is in the therapeutic range (generic acenocoumarol SmPC, AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range. Whenever any drug is added or stopped, use close and frequent coagulation checks, for example twice a week (acenocoumarol SmPC, AEMPS).

Pair details →Phytomenadione →

MajorTicagrelorReversible P2Y12 receptor inhibitor

Mechanism

Acenocoumarol is a coumarin derivative and a vitamin K antagonist that reduces the formation of active clotting factors II, VII, IX and X (acenocoumarol summary of product characteristics, Spanish Agency of Medicines and Medical Devices, AEMPS). Ticagrelor reversibly blocks the platelet P2Y12 receptor and so prevents platelet activation and aggregation. Its own SmPC classes it as a platelet aggregation inhibitor (ticagrelor SmPC, European Medicines Agency, ). The acenocoumarol SmPC lists platelet aggregation inhibitors among drugs that potentiate the anticoagulant or impair haemostasis and increase the risk of bleeding (AEMPS). A study with tolbutamide showed that ticagrelor does not inhibit the CYP2C9 enzyme, so it is unlikely to alter warfarin metabolism (ticagrelor SmPC, EMA). The ticagrelor SmPC does not mention acenocoumarol.

Symptoms

Bleeding in various organs is a common adverse reaction to acenocoumarol, and its risk depends on the dose, the patient's age and the underlying disease (acenocoumarol summary of product characteristics, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol can cause severe bleeding, including haemorrhagic shock, or fatal bleeding (AEMPS). With excessive anticoagulation the most frequent signs are bleeding into the skin, blood in the urine, haematomas, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, gum bleeding and bleeding into the joints (AEMPS). The most frequently reported adverse reactions with ticagrelor are bleeding and shortness of breath (ticagrelor SmPC, European Medicines Agency, ).

Management

Platelet aggregation inhibitors are generally not recommended with acenocoumarol. The acenocoumarol SmPC gives clopidogrel, ticlopidine and acetylsalicylic acid as examples of the class, and ticagrelor belongs to this class according to its own SmPC (acenocoumarol summary of product characteristics, Spanish Agency of Medicines and Medical Devices, AEMPS; ticagrelor SmPC, European Medicines Agency, ). Use the combination only when it is strictly indicated, for example when there is a concurrent indication for oral anticoagulation and antiplatelet therapy, and then test coagulation more often (AEMPS). Whenever any drug is added or withdrawn, monitor coagulation closely and check it often, for example twice a week (AEMPS). Use ticagrelor with caution in patients who take oral anticoagulants within 24 hours of a ticagrelor dose, and in patients at known high risk of bleeding weigh its benefit against that risk (ticagrelor SmPC, EMA). Give ticagrelor with a low maintenance dose of acetylsalicylic acid, 75–150 mg a day, unless it is contraindicated (EMA), and the acenocoumarol SmPC also lists acetylsalicylic acid among drugs that are generally not recommended with acenocoumarol (AEMPS). Before elective surgery, if an antiplatelet effect is not needed, stop ticagrelor 5 days in advance (EMA), and patients on acenocoumarol need close control of anticoagulation before surgery or invasive procedures (AEMPS).

Pair details →Ticagrelor →

ModerateAllopurinolXanthine oxidase inhibitors

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs, both the originator and the generic, list allopurinol among the drugs that can potentiate its anticoagulant effect (AEMPS). According to the Spanish allopurinol SmPC, isolated cases of an increased anticoagulant effect of warfarin and other coumarins have been reported with allopurinol. The SmPC does not explain how this happens (allopurinol SmPC, AEMPS). The documents give data only for other anticoagulants. According to the US label, allopurinol prolongs the half-life of dicoumarol by an unknown mechanism. It may also inhibit the metabolism of warfarin and so potentiate its effect (allopurinol prescribing information, US Food and Drug Administration, ).

Symptoms

The main risk is bleeding from an increased effect of acenocoumarol. Cases of an increased anticoagulant effect have been reported when allopurinol was given with coumarins (allopurinol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With warfarin, allopurinol may increase the anticoagulant effect, so monitor patients for excessive anticoagulation (allopurinol prescribing information, US Food and Drug Administration, ). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. According to the Spanish allopurinol SmPC, all patients on anticoagulants should be monitored carefully (allopurinol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when allopurinol is added and when it is stopped (acenocoumarol SmPCs, AEMPS). When allopurinol is added to warfarin or dicoumarol, the US allopurinol label says to monitor for excessive anticoagulation, check the international normalised ratio (INR) or prothrombin time frequently and adjust the anticoagulant dose. It does not mention acenocoumarol (allopurinol prescribing information, US Food and Drug Administration, ). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).

Pair details →Allopurinol →

ModerateAmoxicillinPenicillins with extended spectrum

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Amoxicillin appears in the list of drugs that can potentiate acenocoumarol in both the originator and the generic SmPC (AEMPS). According to the amoxicillin SmPCs, oral anticoagulants and penicillins have been widely used together without reported interactions. The literature, however, contains cases of a raised INR in people taking acenocoumarol or warfarin who started amoxicillin. The documents do not explain how this happens (AEMPS). Prolonged prothrombin time has also been reported rarely in people treated with amoxicillin (AEMPS). Infection and inflammation can reduce the protein binding of acenocoumarol, so strict medical supervision is needed during such periods (acenocoumarol SmPC, AEMPS).

Symptoms

The main risk is bleeding. The literature reports a raised international normalised ratio (INR) in people taking acenocoumarol or warfarin who started amoxicillin. Prolonged bleeding time and prothrombin time also appear among the very rare adverse effects of amoxicillin itself (amoxicillin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an INR above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. If amoxicillin is needed, check the prothrombin time or the international normalised ratio (INR) carefully when the antibiotic is added and when it is stopped. Adjust the acenocoumarol dose to keep the desired level of anticoagulation (amoxicillin summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; amoxicillin prescribing information, US Food and Drug Administration, ). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added and when it is stopped, including after the end of the antibiotic course (acenocoumarol SmPCs, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).

Pair details →Amoxicillin →

ModerateAmoxicillin + Clavulanic AcidFixed-dose combination: aminopenicillin plus beta-lactamase inhibitor

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs list amoxicillin among drugs that can potentiate acenocoumarol, and the generic SmPC also lists amoxicillin with clavulanic acid (AEMPS). According to the amoxicillin/clavulanic acid SmPC, oral anticoagulants and penicillins have been widely used together without reported interactions. The literature, however, contains cases of a raised INR in people taking warfarin or acenocoumarol who started amoxicillin. The documents do not explain how this happens (AEMPS). Prolonged prothrombin time has also been reported rarely in people treated with amoxicillin/clavulanic acid (AEMPS). Infection and inflammation can reduce the protein binding of acenocoumarol, so strict medical supervision is needed during such periods (acenocoumarol SmPC, AEMPS).

Symptoms

The main risk is bleeding. The literature reports a raised international normalised ratio (INR) in people taking warfarin or acenocoumarol who started amoxicillin. Prolonged bleeding time and prothrombin time also appear among the adverse effects of amoxicillin/clavulanic acid itself (amoxicillin/clavulanic acid summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an INR above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. If amoxicillin/clavulanic acid is needed, check the prothrombin time or the international normalised ratio (INR) carefully after the antibiotic is started and after it is stopped. Adjust the acenocoumarol dose to keep the desired level of anticoagulation (amoxicillin/clavulanic acid summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; amoxicillin/clavulanate prescribing information, US Food and Drug Administration, ). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added and when it is stopped, including after the end of the antibiotic course (acenocoumarol SmPCs, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).

Pair details →Amoxicillin + Clavulanic Acid →

ModerateAtorvastatinHMG-CoA reductase inhibitors (statins)

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist. The Spanish acenocoumarol SmPCs, both the originator and a generic, list atorvastatin among statins that can potentiate its anticoagulant effect (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The documents do not say how atorvastatin produces this effect (AEMPS). The figures in the atorvastatin SmPC come from warfarin. In patients on long-term warfarin, atorvastatin 80 mg a day slightly shortened the prothrombin time over the first 4 days, by about 1.7 seconds. The value returned to normal by day 15 (atorvastatin SmPC, AEMPS). Clinically significant interactions of atorvastatin with anticoagulants have been reported very rarely (atorvastatin SmPC, AEMPS). The US label describes the effect of atorvastatin on prothrombin time during long-term warfarin treatment as not clinically significant (atorvastatin prescribing information, US Food and Drug Administration, ).

Symptoms

If the effect of acenocoumarol increases, the main risk is bleeding (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol can cause serious or fatal bleeding, including haemorrhagic shock. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints, as well as fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain (acenocoumarol SmPC, AEMPS).

Management

No document contraindicates or prohibits this combination, but coagulation is monitored when atorvastatin is started. In people taking a coumarin anticoagulant, measure the prothrombin time before starting atorvastatin and frequently enough early in treatment to make sure there is no significant change. After that, check it at the intervals usual for the anticoagulant (atorvastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Repeat the same steps if the atorvastatin dose is changed or atorvastatin is stopped (atorvastatin SmPC, AEMPS). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week, both when atorvastatin is added and when it is stopped (acenocoumarol SmPCs, AEMPS). With an international normalised ratio (INR) of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt it and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Atorvastatin →

ModerateCapecitabineAntineoplastic, oral prodrug of 5-FU

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist. Liver enzymes, mainly CYP2C9, metabolise it. According to the Spanish generic acenocoumarol summary of product characteristics (SmPC), CYP2C9 inhibitors can potentiate its anticoagulant effect (acenocoumarol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). In a study in patients with cancer, capecitabine raised the area under the concentration curve of S-warfarin by 57% after a single 20 mg dose of warfarin. It raised the maximum international normalised ratio (INR) by 91% and did not change R-warfarin metabolism. These results indicate that capecitabine inhibits CYP2C9 and has no effect on CYP1A2 or CYP3A4 (capecitabine SmPC, European Medicines Agency, ; capecitabine prescribing information, US Food and Drug Administration, ). Altered coagulation parameters and bleeding have been reported when capecitabine was combined with coumarin anticoagulants such as warfarin and phenprocoumon. The US label reports them with vitamin K antagonists, including deaths (capecitabine SmPC, EMA; prescribing information, FDA). The documents contain no study with acenocoumarol, but it belongs to both classes named (acenocoumarol SmPC, AEMPS).

Symptoms

The main risk is bleeding. In patients on a stable dose of a vitamin K antagonist, clinically significant rises in the prothrombin time and the international normalised ratio (INR) have been reported after capecitabine was started. They appeared within several days to several months, and in a few cases within a month after capecitabine was stopped. They were seen in patients with and without liver metastases (capecitabine summary of product characteristics, SmPC, European Medicines Agency, ; capecitabine prescribing information, US Food and Drug Administration, ). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Cancer is one of the risk factors for bleeding during acenocoumarol treatment (acenocoumarol SmPC, AEMPS). Capecitabine itself can cause thrombocytopenia and gastrointestinal bleeding (capecitabine SmPC, EMA).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. When a coumarin anticoagulant is taken with capecitabine, monitor the anticoagulant response closely with the international normalised ratio (INR) or prothrombin time and adjust the anticoagulant dose (capecitabine summary of product characteristics, SmPC, European Medicines Agency, ). According to the US label, check the INR more often and adjust the vitamin K antagonist dose as needed, both during capecitabine treatment and after it is stopped (capecitabine prescribing information, US Food and Drug Administration, ). The acenocoumarol SmPC asks for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added and when it is stopped (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). Acenocoumarol is contraindicated with a platelet count below 50×10⁹/L (acenocoumarol SmPC, AEMPS). Capecitabine is contraindicated in severe thrombocytopenia (capecitabine SmPC, EMA). The US capecitabine label asks for a complete blood count at baseline and before each cycle (FDA). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Capecitabine →

ModerateCarbamazepineAntiepileptics. Carboxamide derivatives

Mechanism

Liver enzymes, mainly CYP2C9, metabolise acenocoumarol, and inducers of CYP2C9, CYP2C19 and CYP3A4 can reduce its anticoagulant effect (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Carbamazepine is a potent inducer of CYP3A4 and other liver enzyme systems (carbamazepine SmPC, AEMPS). According to the US label, it also induces CYP1A2, CYP2B6, CYP2C8, CYP2C9 and CYP2C19 and may lower the levels of drugs mainly metabolised by these enzymes (carbamazepine prescribing information, US Food and Drug Administration, ). The Spanish carbamazepine SmPC names acenocoumarol explicitly among the oral anticoagulants whose plasma levels and effect carbamazepine can reduce or even abolish (carbamazepine SmPC, AEMPS). The acenocoumarol SmPC lists carbamazepine among drugs that can reduce its anticoagulant effect (acenocoumarol SmPC, AEMPS). Of the coumarins, the US carbamazepine label names only warfarin and dicoumarol (carbamazepine prescribing information, FDA).

Symptoms

The effect of acenocoumarol can weaken or even disappear (carbamazepine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The international normalised ratio (INR) then falls below the target range, and protection against clots, the reason for acenocoumarol treatment, weakens. After carbamazepine is stopped, the effect of acenocoumarol can increase again, especially if its dose was raised. With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).

Management

The combination is not contraindicated but needs close coagulation monitoring. The acenocoumarol summary of product characteristics (SmPC) lists carbamazepine among drugs that can reduce its effect. It asks for close and frequent coagulation checks, for example twice a week, both when such a drug is added and when it is stopped (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the Spanish carbamazepine SmPC, the dose of oral anticoagulants, including acenocoumarol, is adjusted to clinical requirements (carbamazepine SmPC, AEMPS). According to the US carbamazepine label, concentration monitoring or dose adjustment may be needed with warfarin (carbamazepine prescribing information, US Food and Drug Administration, ). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Carbamazepine →

ModerateCefditoren pivoxilThird-generation oral cephalosporin

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs list second- and third-generation cephalosporins among antibiotics that can potentiate acenocoumarol. The cefditoren SmPC classifies cefditoren (cefditoren pivoxil) as a third-generation cephalosporin (acenocoumarol and cefditoren SmPCs, AEMPS). According to the cefditoren SmPC, prothrombin activity can fall during cephalosporin treatment. The US label also counts people previously stabilised on anticoagulant therapy among those at risk (cefditoren SmPC, AEMPS; cefditoren prescribing information, US Food and Drug Administration, ). In clinical trials, the incidence of prolonged prothrombin time did not differ between cefditoren and comparator cephalosporins (FDA). Infection and inflammation can reduce the protein binding of acenocoumarol, so strict medical supervision is needed during such periods (acenocoumarol SmPC, AEMPS).

Symptoms

The main risk is bleeding. Rare adverse effects of cefditoren include prolonged coagulation time, thrombocytopenia and gastrointestinal bleeding (cefditoren summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label lists bleeding and prolonged prothrombin time among adverse reactions of the whole cephalosporin class (cefditoren prescribing information, US Food and Drug Administration, ). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. The acenocoumarol summaries of product characteristics (SmPCs) ask for close and frequent coagulation checks, for example twice a week. This applies both when cefditoren is added and when it is stopped, including after the end of the antibiotic course (acenocoumarol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). In people taking anticoagulants, monitor the prothrombin time during cefditoren treatment (cefditoren SmPC, AEMPS). The US label says to give vitamin K as indicated (cefditoren prescribing information, US Food and Drug Administration, ). Adjust the acenocoumarol dose by the prothrombin time and the international normalised ratio (INR). A dose change does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (acenocoumarol SmPC, AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. After bleeding, restart acenocoumarol once the INR is back in the target range (acenocoumarol SmPC, AEMPS).

Pair details →Cefditoren pivoxil →

ModerateCefuroxime axetilSecond-generation oral cephalosporin

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs list second- and third-generation cephalosporins among antibiotics that can potentiate acenocoumarol. The cefuroxime SmPC classifies cefuroxime (cefuroxime axetil) as a second-generation cephalosporin (acenocoumarol and cefuroxime SmPCs, AEMPS). According to the cefuroxime SmPC, use with oral anticoagulants can raise the INR. The documents do not explain how this happens (AEMPS). The US label for cefuroxime axetil lists prolonged prothrombin time among post-marketing reports (cefuroxime axetil prescribing information, US Food and Drug Administration, ). Infection and inflammation can reduce the protein binding of acenocoumarol, so strict medical supervision is needed during such periods (acenocoumarol SmPC, AEMPS).

Symptoms

The main risk is bleeding. According to the cefuroxime summary of product characteristics (SmPC), use with oral anticoagulants can raise the international normalised ratio (INR). Thrombocytopenia is among the uncommon adverse effects of cefuroxime itself (cefuroxime SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label for cefuroxime axetil lists prolonged prothrombin time and thrombocytopenia among post-marketing reports (cefuroxime axetil prescribing information, US Food and Drug Administration, ). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an INR above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. The acenocoumarol summaries of product characteristics (SmPCs) ask for close and frequent coagulation checks, for example twice a week. This applies both when cefuroxime is added and when it is stopped, including after the end of the antibiotic course (acenocoumarol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The cefuroxime SmPC only states that use with oral anticoagulants can raise the international normalised ratio (INR) and gives no specific measures (cefuroxime SmPC, AEMPS). The US cefuroxime axetil label does not list anticoagulants among its interactions (US Food and Drug Administration, ). Adjust the acenocoumarol dose by the prothrombin time and the INR. A dose change does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (acenocoumarol SmPC, AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. After bleeding, restart acenocoumarol once the INR is back in the target range (acenocoumarol SmPC, AEMPS).

Pair details →Cefuroxime axetil →

ModerateChloramphenicolAmphenicol antibiotic for systemic use

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs list chloramphenicol among antibiotics that can potentiate acenocoumarol but do not describe a mechanism for it. The originator acenocoumarol SmPC lists general mechanisms of coumarin interactions: impaired absorption, inhibition or induction of liver enzymes, mainly CYP2C9, and reduced availability of vitamin K (acenocoumarol SmPCs, AEMPS). The chloramphenicol documents say nothing about anticoagulants. In Spain, chloramphenicol is available only as eye ointments and as skin ointments with hydrocortisone. Among interactions, the US label for intravenous chloramphenicol names only drugs that may cause bone marrow depression (chloramphenicol SmPCs, AEMPS; chloramphenicol prescribing information, US Food and Drug Administration, ). Infection and inflammation can reduce the protein binding of acenocoumarol, so strict medical supervision is needed during such periods (acenocoumarol SmPC, AEMPS).

Symptoms

The main risk is bleeding, because chloramphenicol can potentiate acenocoumarol. Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol summaries of product characteristics, SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints (AEMPS). Chloramphenicol itself can cause serious, sometimes fatal, blood dyscrasias such as aplastic anaemia, thrombocytopenia and granulocytopenia (chloramphenicol prescribing information, US Food and Drug Administration, ). After topical use such reactions are rare, but bone marrow aplasia has also occurred after the eye ointment (chloramphenicol eye ointment SmPC, AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. The acenocoumarol summaries of product characteristics (SmPCs) ask for close and frequent coagulation checks, for example twice a week. This applies both when chloramphenicol is added and when it is stopped (acenocoumarol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPCs do not specify the chloramphenicol formulation (AEMPS). The Spanish chloramphenicol ointment SmPCs say nothing about anticoagulants (AEMPS). According to the eye ointment SmPC, chloramphenicol applied to the eye can be absorbed into the aqueous humour and reach the systemic circulation. Specific data on systemic absorption are lacking. According to the SmPC of the skin ointment with hydrocortisone, absorption of a very small amount through damaged skin cannot be excluded (chloramphenicol SmPCs, AEMPS). During intravenous chloramphenicol treatment, do baseline blood tests and repeat them about every two days. Stop chloramphenicol if reticulocytopenia, leukopenia, thrombocytopenia, anaemia or other blood changes attributable to it appear (chloramphenicol prescribing information, US Food and Drug Administration, ). Acenocoumarol is contraindicated in thrombocytopenia with a platelet count below 50 × 10⁹/L (acenocoumarol SmPC, AEMPS). Adjust the acenocoumarol dose by the prothrombin time and the international normalised ratio (INR). A dose change does not show in the prothrombin time for at least 36 hours. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Chloramphenicol →

ModerateCiprofloxacinFluoroquinolone antibacterials

Mechanism

In the liver, CYP2C9 is the main enzyme that metabolises acenocoumarol, and CYP1A2 and CYP2C19 also metabolise its more active R-enantiomer (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Ciprofloxacin inhibits CYP1A2, and the Spanish SmPC calls it a moderate inhibitor of this enzyme (ciprofloxacin SmPC, AEMPS; ciprofloxacin prescribing information, US Food and Drug Administration, ). The Spanish SmPC states that ciprofloxacin can potentiate vitamin K antagonists and names acenocoumarol explicitly among them. The contribution of ciprofloxacin itself to a rise in the international normalised ratio (INR) cannot be determined precisely, because the risk depends on the infection, age and general condition of the patient (AEMPS; FDA). The documents do not say whether the INR rise is linked to CYP1A2 inhibition. The acenocoumarol SmPCs list fluoroquinolones, and the generic SmPC names ciprofloxacin explicitly, among the drugs that can potentiate acenocoumarol (acenocoumarol SmPCs, AEMPS). Infection and inflammation can reduce the protein binding of acenocoumarol, so strict medical supervision is needed during such periods (acenocoumarol SmPC, AEMPS).

Symptoms

The main risk is bleeding. According to the Spanish ciprofloxacin summary of product characteristics (SmPC), ciprofloxacin can potentiate acenocoumarol and other vitamin K antagonists and raise the international normalised ratio (INR). Post-marketing reports include both prolongation and shortening of the prothrombin time (ciprofloxacin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; ciprofloxacin prescribing information, US Food and Drug Administration, ). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an INR above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. The Spanish ciprofloxacin SmPC names acenocoumarol and advises frequent checks of the international normalised ratio (INR) during and just after co-administration (ciprofloxacin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label advises caution with oral anticoagulants and frequent checks of the prothrombin time and INR during and shortly after co-administration (ciprofloxacin prescribing information, US Food and Drug Administration, ). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added and when it is stopped, including after the end of a ciprofloxacin course (acenocoumarol SmPCs, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).

Pair details →Ciprofloxacin →

ModerateCitalopramSSRI (selective serotonin reuptake inhibitor)

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs name citalopram among the selective serotonin reuptake inhibitors (SSRIs) that can potentiate its anticoagulant effect (acenocoumarol SmPCs, AEMPS). SSRIs raise the risk of bleeding on their own, and anticoagulants may add to this risk (citalopram SmPC, AEMPS; citalopram prescribing information, US Food and Drug Administration, ). Citalopram hardly inhibits liver enzymes. Its effect on CYP2C9 is negligible, and its effect on CYP1A2 and CYP2C19, which take part in the metabolism of R-acenocoumarol, is weak. With warfarin, there were no changes or only very small changes of no clinical importance (citalopram and acenocoumarol SmPCs, AEMPS). The documents contain no study with acenocoumarol. Citalopram 40 mg a day for 21 days did not change warfarin pharmacokinetics but raised the prothrombin time by 5%. The clinical significance of this is unknown (citalopram prescribing information, FDA).

Symptoms

The main risk is bleeding. With selective serotonin reuptake inhibitors (SSRIs), altered skin bleeding time and bleeding events have been described, such as bruising, gynaecological and gastrointestinal bleeding and other skin or mucosal bleeding (citalopram summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the US label, such events range from bruising, haematomas, nosebleeds and petechiae to life-threatening bleeding (citalopram prescribing information, US Food and Drug Administration, ). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. The acenocoumarol summaries of product characteristics (SmPCs) name citalopram among the drugs that can potentiate its effect. They ask for close and frequent coagulation checks, for example twice a week. This applies both when such a drug is added and when it is stopped (acenocoumarol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). Use citalopram with caution in patients on anticoagulants and in those with a history of bleeding disorders (citalopram SmPC, AEMPS). The US label says to inform patients of the increased risk of bleeding and, in patients taking warfarin, to monitor the international normalised ratio (INR) carefully (citalopram prescribing information, US Food and Drug Administration, ). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (acenocoumarol SmPC, AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. After the bleeding, restart acenocoumarol once the INR is back in the target range (acenocoumarol SmPC, AEMPS).

Pair details →Citalopram →

ModerateClarithromycinMacrolide antibiotic

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In the liver, CYP2C9 is the main enzyme that metabolises acenocoumarol, and CYP1A2 and CYP2C19 also metabolise its R-enantiomer (AEMPS). Clarithromycin inhibits CYP3A and can raise the levels of drugs cleared mainly by this enzyme. The Spanish clarithromycin SmPCs include oral anticoagulants, for example warfarin, among such drugs (clarithromycin SmPC, AEMPS). Post-marketing reports suggest that clarithromycin may potentiate oral anticoagulants (clarithromycin prescribing information, US Food and Drug Administration, ). The Spanish SmPC of a generic acenocoumarol explicitly names clarithromycin among drugs that can potentiate acenocoumarol (AEMPS). Infection and inflammation can reduce the protein binding of acenocoumarol, so strict medical supervision is needed during such periods (acenocoumarol SmPC, AEMPS).

Symptoms

The main risk is bleeding. With warfarin, the clarithromycin labels describe a risk of serious haemorrhage and significant rises in the international normalised ratio (INR) and prothrombin time. They give no separate information on acenocoumarol (clarithromycin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; clarithromycin prescribing information, US Food and Drug Administration, ). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an INR above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. Check the international normalised ratio (INR) and prothrombin time frequently for as long as the person takes clarithromycin with an oral anticoagulant (clarithromycin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; clarithromycin prescribing information, US Food and Drug Administration, ). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added and when it is stopped, including after the end of the antibiotic course (acenocoumarol SmPCs, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).

Pair details →Clarithromycin →

ModerateCo-trimoxazoleSulfonamide-trimethoprim combination

Mechanism

In the liver, CYP2C9 is the main enzyme that metabolises acenocoumarol (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Sulfamethoxazole, a component of co-trimoxazole, inhibits CYP2C9, and trimethoprim inhibits CYP2C8 (co-trimoxazole prescribing information, US Food and Drug Administration, ). According to the Spanish co-trimoxazole SmPC, co-trimoxazole potentiates warfarin through stereoselective inhibition of its metabolism, and sulfamethoxazole can displace warfarin from its binding sites on plasma albumin in vitro. Data exist only for warfarin (co-trimoxazole SmPC, AEMPS). The acenocoumarol SmPCs list sulfonamides, co-trimoxazole included, among the drugs that can potentiate acenocoumarol. Acenocoumarol itself is 98.7% bound to plasma proteins, mainly albumin (acenocoumarol SmPCs, AEMPS). Infection and inflammation can reduce the protein binding of acenocoumarol, so strict medical supervision is needed during such periods (acenocoumarol SmPC, AEMPS).

Symptoms

The main risk is bleeding. According to the US label, co-trimoxazole may prolong the prothrombin time in people receiving warfarin, and hypoprothrombinaemia, a low level of prothrombin in the blood, is among its adverse reactions (co-trimoxazole prescribing information, US Food and Drug Administration, ). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. Using warfarin as the example, the Spanish co-trimoxazole SmPC advises careful monitoring of anticoagulant therapy during co-trimoxazole treatment (co-trimoxazole summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label says to keep the interaction in mind when giving co-trimoxazole to someone already on anticoagulant therapy. It also says to reassess coagulation by checking the international normalised ratio (INR) and the prothrombin time (co-trimoxazole prescribing information, US Food and Drug Administration, ). The same label also says in general terms to avoid co-trimoxazole with substrates of CYP2C8 and CYP2C9. For warfarin, a CYP2C9 substrate, its interaction table gives only prothrombin time and INR monitoring (FDA). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added and when it is stopped, including after the end of a co-trimoxazole course (acenocoumarol SmPCs, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).

Pair details →Co-trimoxazole →

ModerateCyproterone acetate + EthinylestradiolAntiandrogenic COC

Mechanism

Acenocoumarol is a vitamin K antagonist: it reduces the formation of the vitamin K-dependent clotting factors II, VII, IX and X (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its anticoagulant effect but gives no mechanism for them. As general routes of coumarin interactions, it names impaired absorption, inhibition or induction of liver enzymes, mainly CYP2C9, and reduced availability of vitamin K (acenocoumarol SmPC, AEMPS). Cyproterone acetate/ethinylestradiol is prescribed for acne and hirsutism. According to its own SmPC, it inhibits ovulation and acts as a hormonal contraceptive. It is taken by mouth, and the SmPC applies the warnings for combined oral contraceptives to it (cyproterone acetate/ethinylestradiol SmPC, AEMPS). The same SmPC says that combined oral contraceptives reduce the effect of oral anticoagulants, probably because of an antagonistic effect on some clotting factors. However, they potentiate the effect of acenocoumarol. In women taking the product, laboratory tests can show raised prothrombin and factors VII, VIII, IX and X (cyproterone acetate/ethinylestradiol SmPC, AEMPS). So the documents disagree on the direction of the change. The acenocoumarol SmPC says oral contraceptives can reduce its effect, and the cyproterone acetate/ethinylestradiol SmPC says they can potentiate it.

Symptoms

The international normalised ratio (INR) can shift either way. According to the acenocoumarol summary of product characteristics (SmPC), oral contraceptives can reduce the effect of acenocoumarol. The INR then falls below the target range, and protection against clots weakens (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the cyproterone acetate/ethinylestradiol SmPC, the effect of acenocoumarol can increase instead (cyproterone acetate/ethinylestradiol SmPC, AEMPS). The product itself raises the risk of venous thromboembolism, and epidemiological studies link hormonal contraceptives to a higher risk of arterial thromboembolism. Signs of thrombosis listed in its SmPC include unusual pain or swelling of one leg, sudden severe chest pain, sudden breathlessness, slurred speech and sudden weakness or numbness of one side or part of the body (cyproterone acetate/ethinylestradiol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).

Management

The combination itself is not contraindicated. However, section 4.3 of the cyproterone acetate/ethinylestradiol summary of product characteristics (SmPC) rules out the product in current or past venous thrombosis (deep vein thrombosis, pulmonary embolism). If such a condition first appears during use, stop the product at once. So if acenocoumarol is prescribed for venous thrombosis, the product is contraindicated (cyproterone acetate/ethinylestradiol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The same SmPC contraindicates the product in current or past arterial thrombosis, for example myocardial infarction, and in current or past stroke. It is also contraindicated in inherited or acquired predisposition to thrombosis, including antiphospholipid antibodies, in thrombogenic valvular disease and with one severe or several risk factors for thrombosis. The SmPC lists valvular heart disease and atrial fibrillation among factors that raise the risk of arterial thromboembolism and stroke (cyproterone acetate/ethinylestradiol SmPC, AEMPS). The indications of acenocoumarol include atrial fibrillation, the period after myocardial infarction, rheumatic mitral valve disease, prosthetic heart valves and antiphospholipid syndrome (acenocoumarol SmPC, AEMPS). If thrombosis is suspected or confirmed, stop the product and choose a suitable contraceptive method, because coumarins are teratogenic (cyproterone acetate/ethinylestradiol SmPC, AEMPS). Acenocoumarol is contraindicated in pregnancy, and women of childbearing potential must use effective contraception during treatment (acenocoumarol SmPC, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its effect. It asks for close and frequent coagulation checks, for example twice a week, when such a drug is added or stopped. A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. Base dose adjustments on the total weekly dose (acenocoumarol SmPCs, AEMPS). The cyproterone acetate/ethinylestradiol SmPC, by contrast, says that combined oral contraceptives potentiate the effect of acenocoumarol, so the international normalised ratio (INR) may shift either way (cyproterone acetate/ethinylestradiol SmPC, AEMPS). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Cyproterone acetate + Ethinylestradiol →

ModerateDrospirenone + ethinylestradiolCombined oral contraceptives – antimineralocorticoid progestin

Mechanism

Acenocoumarol is a vitamin K antagonist: it reduces the formation of the vitamin K-dependent clotting factors II, VII, IX and X (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its anticoagulant effect but gives no mechanism for them. As general routes of coumarin interactions, it names impaired absorption, inhibition or induction of liver enzymes, mainly CYP2C9, and reduced availability of vitamin K (acenocoumarol SmPC, AEMPS). Combined hormonal contraceptives raise the risk of venous thromboembolism compared with non-use. Epidemiological studies also link them to a higher risk of arterial thromboembolism, including myocardial infarction and stroke. Coagulation and fibrinolysis parameters can change, usually within the normal range (drospirenone/ethinylestradiol SmPC, AEMPS).

Symptoms

The anticoagulant effect of acenocoumarol can decrease. The international normalised ratio (INR) then falls below the target range, and protection against clots, the reason for acenocoumarol treatment, weakens (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The contraceptive itself raises the risk of thrombosis. Its SmPC lists signs that need urgent medical help: swelling and pain in one leg, sudden breathlessness, sharp chest pain, sudden numbness or weakness of the face, arm or leg, especially on one side, and difficulty speaking (drospirenone/ethinylestradiol SmPC, AEMPS). After the contraceptive is stopped, the effect of acenocoumarol can increase again, especially if its dose had been raised. With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).

Management

The combination itself is not contraindicated. However, section 4.3 of the drospirenone/ethinylestradiol summary of product characteristics (SmPC) rules out a combined hormonal contraceptive in current or past venous thromboembolism, for example deep vein thrombosis or pulmonary embolism. This applies even when current venous thromboembolism is treated with anticoagulants. If such a condition first appears during use, stop the contraceptive at once. So if acenocoumarol is prescribed for venous thromboembolism, the contraceptive is contraindicated (drospirenone/ethinylestradiol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The same SmPC contraindicates the contraceptive in current or past arterial thromboembolism, for example myocardial infarction, and in current or past stroke. It is also contraindicated in known predisposition to arterial thromboembolism, such as antiphospholipid antibodies. The SmPC lists valvular heart disease and atrial fibrillation among risk factors for arterial thromboembolism. With several risk factors or one severe risk factor, the contraceptive is contraindicated (drospirenone/ethinylestradiol SmPC, AEMPS). The indications of acenocoumarol include atrial fibrillation, the period after myocardial infarction, rheumatic mitral valve disease, prosthetic heart valves and antiphospholipid syndrome (acenocoumarol SmPC, AEMPS). The US label contraindicates drospirenone/ethinylestradiol in women at high risk of arterial or venous thrombotic disease. Examples include current or past deep vein thrombosis or pulmonary embolism and thrombogenic valvular or rhythm disease of the heart, such as atrial fibrillation (drospirenone/ethinylestradiol prescribing information, US Food and Drug Administration, ). If venous or arterial thromboembolism is suspected or confirmed, stop the contraceptive. If anticoagulant treatment is started, switch to a suitable alternative contraceptive method, because coumarins are teratogenic (drospirenone/ethinylestradiol SmPC, AEMPS). Acenocoumarol is contraindicated in pregnancy, and women of childbearing potential must use effective contraception during treatment (acenocoumarol SmPC, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its effect. It asks for close and frequent coagulation checks, for example twice a week, when such a drug is added or stopped. A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. Base dose adjustments on the total weekly dose (acenocoumarol SmPCs, AEMPS). With an international normalised ratio (INR) of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Drospirenone + ethinylestradiol →

ModerateEscitalopramSelective serotonin reuptake inhibitors (SSRIs)

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs list selective serotonin reuptake inhibitors (SSRIs) among the drugs that can potentiate its effect. Escitalopram is not among the examples, but the class is named without restriction, and the escitalopram SmPC itself classes it as an SSRI (AEMPS). According to the escitalopram labels, escitalopram may alter the effect of oral anticoagulants. SSRIs also raise the risk of bleeding on their own, and anticoagulants may add to this risk (escitalopram SmPC, AEMPS; escitalopram prescribing information, US Food and Drug Administration, ). The documents contain no study with acenocoumarol. Racemic citalopram 40 mg a day for 21 days did not change warfarin pharmacokinetics but raised the prothrombin time by 5%. The clinical significance of this is unknown (escitalopram prescribing information, FDA). Based on in vitro studies, the Spanish escitalopram SmPC calls it a weak inhibitor of CYP2C19, which takes part in the metabolism of the R-enantiomer of acenocoumarol together with CYP1A2 (the main enzyme is CYP2C9). The US label found no in vitro inhibition of CYP2C9 or CYP2C19 (escitalopram and acenocoumarol SmPCs, AEMPS; FDA).

Symptoms

The main risk is bleeding. Bleeding into the skin, such as ecchymosis and purpura, has been reported with selective serotonin reuptake inhibitors (SSRIs). Gastrointestinal bleeding, including rectal bleeding, appears among the adverse effects of escitalopram (escitalopram summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the US label, such bleeding ranges from ecchymoses, haematomas, nosebleeds and petechiae to life-threatening haemorrhage (escitalopram prescribing information, US Food and Drug Administration, ). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. In patients on an oral anticoagulant, monitor coagulation closely when escitalopram is started and when it is stopped (escitalopram summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when escitalopram is added and when it is stopped (acenocoumarol SmPCs, AEMPS). The Spanish escitalopram SmPC recommends caution with oral anticoagulants and in patients prone to bleeding. The US label says to inform patients of the increased risk of bleeding (escitalopram SmPC, AEMPS; escitalopram prescribing information, US Food and Drug Administration, ). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).

Pair details →Escitalopram →

ModerateEstradiol + Nomegestrol acetateMonophasic COC with natural estrogen

Mechanism

Acenocoumarol is a vitamin K antagonist: it reduces the formation of the vitamin K-dependent clotting factors II, VII, IX and X (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its anticoagulant effect but gives no mechanism for them. As general routes of coumarin interactions, it names impaired absorption, inhibition or induction of liver enzymes, mainly CYP2C9, and reduced availability of vitamin K (acenocoumarol SmPC, AEMPS). Combined hormonal contraceptives raise the risk of venous thromboembolism compared with non-use. Epidemiological studies also link them to a higher risk of arterial thromboembolism, including myocardial infarction and stroke. Coagulation and fibrinolysis parameters can change, usually within the normal range (estradiol/nomegestrol acetate SmPC, European Medicines Agency, ).

Symptoms

The anticoagulant effect of acenocoumarol can decrease. The international normalised ratio (INR) then falls below the target range, and protection against clots, the reason for acenocoumarol treatment, weakens (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The contraceptive itself raises the risk of thrombosis. Its SmPC lists signs that need urgent medical help: swelling and pain in one leg, sudden breathlessness, sharp chest pain, sudden numbness or weakness of the face, arm or leg, especially on one side, and difficulty speaking (estradiol/nomegestrol acetate SmPC, European Medicines Agency, ). After the contraceptive is stopped, the effect of acenocoumarol can increase again, especially if its dose had been raised. With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).

Management

The combination itself is not contraindicated. However, section 4.3 of the estradiol/nomegestrol acetate summary of product characteristics (SmPC) rules out a combined hormonal contraceptive in current or past venous thromboembolism, for example deep vein thrombosis or pulmonary embolism. This applies even when current venous thromboembolism is treated with anticoagulants. If such a condition first appears during use, stop the contraceptive at once. So if acenocoumarol is prescribed for venous thromboembolism, the contraceptive is contraindicated (estradiol/nomegestrol acetate SmPC, European Medicines Agency, ). The same SmPC contraindicates the contraceptive in current or past arterial thromboembolism, for example myocardial infarction, and in current or past stroke. It is also contraindicated in known predisposition to arterial thromboembolism, such as antiphospholipid antibodies. The SmPC lists valvular heart disease and atrial fibrillation among risk factors for arterial thromboembolism. With several risk factors or one severe risk factor, the contraceptive is contraindicated (estradiol/nomegestrol acetate SmPC, EMA). The indications of acenocoumarol include atrial fibrillation, the period after myocardial infarction, rheumatic mitral valve disease, prosthetic heart valves and antiphospholipid syndrome (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol is contraindicated in pregnancy, and women of childbearing potential must use effective contraception during treatment (acenocoumarol SmPC, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its effect. It asks for close and frequent coagulation checks, for example twice a week, when such a drug is added or stopped. A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. Base dose adjustments on the total weekly dose (acenocoumarol SmPCs, AEMPS). With an international normalised ratio (INR) of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Estradiol + Nomegestrol acetate →

ModerateEstradiol valerate + DienogestCOC with natural estrogen (quadriphasic)

Mechanism

Acenocoumarol is a vitamin K antagonist: it reduces the formation of the vitamin K-dependent clotting factors II, VII, IX and X (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its anticoagulant effect but gives no mechanism for them. As general routes of coumarin interactions, it names impaired absorption, inhibition or induction of liver enzymes, mainly CYP2C9, and reduced availability of vitamin K (acenocoumarol SmPC, AEMPS). Combined hormonal contraceptives raise the risk of venous thromboembolism compared with non-use. Epidemiological studies also link them to a higher risk of arterial thromboembolism, including myocardial infarction and stroke. Coagulation and fibrinolysis parameters can change, usually within the normal range (estradiol valerate/dienogest SmPC, AEMPS).

Symptoms

The anticoagulant effect of acenocoumarol can decrease. The international normalised ratio (INR) then falls below the target range, and protection against clots, the reason for acenocoumarol treatment, weakens (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The contraceptive itself raises the risk of thrombosis. Its SmPC lists signs that need urgent medical help: swelling and pain in one leg, sudden breathlessness, sharp chest pain, sudden numbness or weakness of the face, arm or leg, especially on one side, and difficulty speaking (estradiol valerate/dienogest SmPC, AEMPS). After the contraceptive is stopped, the effect of acenocoumarol can increase again, especially if its dose had been raised. With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).

Management

The combination itself is not contraindicated. However, section 4.3 of the estradiol valerate/dienogest summary of product characteristics (SmPC) rules out a combined hormonal contraceptive in current or past venous thromboembolism, for example deep vein thrombosis or pulmonary embolism. This applies even when current venous thromboembolism is treated with anticoagulants. If such a condition first appears during use, stop the contraceptive at once. So if acenocoumarol is prescribed for venous thromboembolism, the contraceptive is contraindicated (estradiol valerate/dienogest SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The same SmPC contraindicates the contraceptive in current or past arterial thromboembolism, for example myocardial infarction, and in current or past stroke. It is also contraindicated in known predisposition to arterial thromboembolism, such as antiphospholipid antibodies. The SmPC lists valvular heart disease and atrial fibrillation among risk factors for arterial thromboembolism. With several risk factors or one severe risk factor, the contraceptive is contraindicated (estradiol valerate/dienogest SmPC, AEMPS). The indications of acenocoumarol include atrial fibrillation, the period after myocardial infarction, rheumatic mitral valve disease, prosthetic heart valves and antiphospholipid syndrome (acenocoumarol SmPC, AEMPS). The US label contraindicates estradiol valerate/dienogest in women at high risk of arterial or venous thrombotic disease. Examples include current or past deep vein thrombosis or pulmonary embolism and thrombogenic valvular or rhythm disease of the heart, such as atrial fibrillation (estradiol valerate/dienogest prescribing information, US Food and Drug Administration, ). If venous or arterial thromboembolism is suspected or confirmed, stop the contraceptive. If anticoagulant treatment is started, switch to a suitable alternative contraceptive method, because coumarins are teratogenic (estradiol valerate/dienogest SmPC, AEMPS). Acenocoumarol is contraindicated in pregnancy, and women of childbearing potential must use effective contraception during treatment (acenocoumarol SmPC, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its effect. It asks for close and frequent coagulation checks, for example twice a week, when such a drug is added or stopped. A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. Base dose adjustments on the total weekly dose (acenocoumarol SmPCs, AEMPS). With an international normalised ratio (INR) of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Estradiol valerate + Dienogest →

ModerateEthinylestradiol + DesogestrelCombined oral contraceptives (COC), third generation

Mechanism

Acenocoumarol is a vitamin K antagonist: it reduces the formation of the vitamin K-dependent clotting factors II, VII, IX and X (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its anticoagulant effect but gives no mechanism for them. As general routes of coumarin interactions, it names impaired absorption, inhibition or induction of liver enzymes, mainly CYP2C9, and reduced availability of vitamin K (acenocoumarol SmPC, AEMPS). Combined hormonal contraceptives raise the risk of venous thromboembolism compared with non-use. Epidemiological studies also link them to a higher risk of arterial thromboembolism, including myocardial infarction and stroke. Coagulation and fibrinolysis parameters can change, usually within the normal range (desogestrel/ethinylestradiol SmPC, AEMPS). According to the US desogestrel/ethinylestradiol label, laboratory tests in women taking oral contraceptives can show raised prothrombin and factors VII, VIII, IX and X and lowered antithrombin III (desogestrel/ethinylestradiol prescribing information, US Food and Drug Administration, ).

Symptoms

The anticoagulant effect of acenocoumarol can decrease. The international normalised ratio (INR) then falls below the target range, and protection against clots, the reason for acenocoumarol treatment, weakens (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The contraceptive itself raises the risk of thrombosis. Its SmPC lists signs that need urgent medical help: swelling and pain in one leg, sudden breathlessness, sharp chest pain, sudden numbness or weakness of the face, arm or leg, especially on one side, and difficulty speaking (desogestrel/ethinylestradiol SmPC, AEMPS). After the contraceptive is stopped, the effect of acenocoumarol can increase again, especially if its dose had been raised. With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).

Management

The combination itself is not contraindicated. However, section 4.3 of the desogestrel/ethinylestradiol summary of product characteristics (SmPC) rules out a combined hormonal contraceptive in current or past venous thromboembolism, for example deep vein thrombosis or pulmonary embolism. This applies even when current venous thromboembolism is treated with anticoagulants. If such a condition first appears during use, stop the contraceptive at once. So if acenocoumarol is prescribed for venous thromboembolism, the contraceptive is contraindicated (desogestrel/ethinylestradiol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The same SmPC contraindicates the contraceptive in current or past arterial thromboembolism, for example myocardial infarction, and in current or past stroke. It is also contraindicated in known predisposition to arterial thromboembolism, such as antiphospholipid antibodies. The SmPC lists valvular heart disease and atrial fibrillation among risk factors for arterial thromboembolism. With several risk factors or one severe risk factor, the contraceptive is contraindicated (desogestrel/ethinylestradiol SmPC, AEMPS). The indications of acenocoumarol include atrial fibrillation, the period after myocardial infarction, rheumatic mitral valve disease, prosthetic heart valves and antiphospholipid syndrome (acenocoumarol SmPC, AEMPS). The US label contraindicates desogestrel/ethinylestradiol in current or past thrombophlebitis or thromboembolic disorders, in known thrombophilic conditions and in valvular heart disease with complications (desogestrel/ethinylestradiol prescribing information, US Food and Drug Administration, ). Acenocoumarol is contraindicated in pregnancy, and women of childbearing potential must use effective contraception during treatment (acenocoumarol SmPC, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its effect. It asks for close and frequent coagulation checks, for example twice a week, when such a drug is added or stopped. A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. Base dose adjustments on the total weekly dose (acenocoumarol SmPCs, AEMPS). With an international normalised ratio (INR) of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Ethinylestradiol + Desogestrel →

ModerateEthinylestradiol + GestodeneCOC third generation with gestodene

Mechanism

Acenocoumarol is a vitamin K antagonist: it reduces the formation of the vitamin K-dependent clotting factors II, VII, IX and X (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its anticoagulant effect but gives no mechanism for them. As general routes of coumarin interactions, it names impaired absorption, inhibition or induction of liver enzymes, mainly CYP2C9, and reduced availability of vitamin K (acenocoumarol SmPC, AEMPS). According to the Spanish gestodene/ethinylestradiol SmPC, combined oral contraceptives reduce the effect of oral anticoagulants, probably because of an antagonistic effect on some clotting factors. However, they potentiate the effect of acenocoumarol. In women taking them, laboratory tests can show raised prothrombin and factors VII, VIII, IX and X and lowered antithrombin III (gestodene/ethinylestradiol SmPC, AEMPS). So the documents disagree on the direction of the change. The acenocoumarol SmPC says oral contraceptives can reduce its effect, and the contraceptive SmPC says they can potentiate it. The contraceptive itself raises the risk of venous thromboembolism, and epidemiological studies link it to a higher risk of myocardial infarction and stroke (gestodene/ethinylestradiol SmPC, AEMPS).

Symptoms

The international normalised ratio (INR) can shift either way. According to the acenocoumarol summary of product characteristics (SmPC), oral contraceptives can reduce the effect of acenocoumarol. The INR then falls below the target range, and protection against clots weakens (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the contraceptive SmPC, the effect of acenocoumarol can increase instead (gestodene/ethinylestradiol SmPC, AEMPS). The contraceptive itself raises the risk of thrombosis. Its SmPC lists signs that need urgent medical help: swelling and pain in one leg, sudden breathlessness, sharp chest pain, sudden numbness or weakness of the face, arm or leg, especially on one side, and difficulty speaking (gestodene/ethinylestradiol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).

Management

The combination itself is not contraindicated. However, section 4.3 of the gestodene/ethinylestradiol summary of product characteristics (SmPC) rules out a combined hormonal contraceptive in current or past venous thromboembolism, for example deep vein thrombosis or pulmonary embolism. This applies even when current venous thromboembolism is treated with anticoagulants. If such a condition first appears during use, stop the contraceptive at once. So if acenocoumarol is prescribed for venous thromboembolism, the contraceptive is contraindicated (gestodene/ethinylestradiol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The same SmPC contraindicates the contraceptive in current or past arterial thromboembolism, for example myocardial infarction, and in current or past stroke. It is also contraindicated in known predisposition to arterial thromboembolism, such as antiphospholipid antibodies, and in thrombogenic valvular disease and thrombogenic arrhythmias (gestodene/ethinylestradiol SmPC, AEMPS). The indications of acenocoumarol include atrial fibrillation, the period after myocardial infarction, rheumatic mitral valve disease, prosthetic heart valves and antiphospholipid syndrome (acenocoumarol SmPC, AEMPS). Acenocoumarol is contraindicated in pregnancy, and women of childbearing potential must use effective contraception during treatment (acenocoumarol SmPC, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its effect. It asks for close and frequent coagulation checks, for example twice a week, when such a drug is added or stopped. A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. Base dose adjustments on the total weekly dose (acenocoumarol SmPCs, AEMPS). The contraceptive SmPC, by contrast, says that combined oral contraceptives potentiate the effect of acenocoumarol, so the international normalised ratio (INR) may shift either way (gestodene/ethinylestradiol SmPC, AEMPS). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Ethinylestradiol + Gestodene →

ModerateEthinylestradiol + LevonorgestrelCombined oral contraceptives (COC), second generation

Mechanism

Acenocoumarol is a vitamin K antagonist: it reduces the formation of the vitamin K-dependent clotting factors II, VII, IX and X (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its anticoagulant effect but gives no mechanism for them. As general routes of coumarin interactions, it names impaired absorption, inhibition or induction of liver enzymes, mainly CYP2C9, and reduced availability of vitamin K (acenocoumarol SmPC, AEMPS). According to the Spanish SmPC of Microgynon (levonorgestrel/ethinylestradiol), combined oral contraceptives reduce the effect of oral anticoagulants, probably because of an antagonistic effect on some clotting factors. However, they potentiate the effect of acenocoumarol. In women taking them, laboratory tests can show raised prothrombin and factors VII, VIII, IX and X and lowered antithrombin III (levonorgestrel/ethinylestradiol SmPC, AEMPS). So the documents disagree on the direction of the change. The acenocoumarol SmPC says oral contraceptives can reduce its effect, and the Microgynon SmPC says they can potentiate it. The contraceptive itself raises the risk of venous thromboembolism, and epidemiological studies link it to a higher risk of myocardial infarction and stroke (levonorgestrel/ethinylestradiol SmPCs, AEMPS).

Symptoms

The international normalised ratio (INR) can shift either way. According to the acenocoumarol summary of product characteristics (SmPC), oral contraceptives can reduce the effect of acenocoumarol. The INR then falls below the target range, and protection against clots weakens (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the Microgynon SmPC, the effect of acenocoumarol can increase instead (levonorgestrel/ethinylestradiol SmPC, AEMPS). The contraceptive itself raises the risk of thrombosis. Its SmPC lists signs that need urgent medical help: swelling and pain in one leg, sudden breathlessness, sharp chest pain, sudden numbness or weakness of the face, arm or leg, especially on one side, and difficulty speaking (levonorgestrel/ethinylestradiol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).

Management

The combination itself is not contraindicated. However, section 4.3 of the levonorgestrel/ethinylestradiol summaries of product characteristics (SmPCs) rules out a combined hormonal contraceptive in current or past venous thromboembolism, for example deep vein thrombosis or pulmonary embolism. This applies even when current venous thromboembolism is treated with anticoagulants. If such a condition first appears during use, stop the contraceptive at once. So if acenocoumarol is prescribed for venous thromboembolism, the contraceptive is contraindicated (levonorgestrel/ethinylestradiol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The same SmPCs contraindicate the contraceptive in current or past arterial thromboembolism, for example myocardial infarction, and in current or past stroke. They also contraindicate it in thrombogenic valvular disease and thrombogenic rhythm disorders. The Microgynon SmPC adds known predisposition to arterial thromboembolism, such as antiphospholipid antibodies (levonorgestrel/ethinylestradiol SmPCs, AEMPS). The indications of acenocoumarol include atrial fibrillation, the period after myocardial infarction, rheumatic mitral valve disease, prosthetic heart valves and antiphospholipid syndrome (acenocoumarol SmPC, AEMPS). The US label contraindicates levonorgestrel/ethinylestradiol in women at high risk of arterial or venous thrombotic disease. Examples include current or past deep vein thrombosis or pulmonary embolism and thrombogenic valvular or rhythm disease of the heart, such as atrial fibrillation (levonorgestrel/ethinylestradiol prescribing information, US Food and Drug Administration, ). Acenocoumarol is contraindicated in pregnancy, and women of childbearing potential must use effective contraception during treatment (acenocoumarol SmPC, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its effect. It asks for close and frequent coagulation checks, for example twice a week, when such a drug is added or stopped. A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. Base dose adjustments on the total weekly dose (acenocoumarol SmPCs, AEMPS). The Microgynon SmPC, by contrast, says that combined oral contraceptives potentiate the effect of acenocoumarol, so the international normalised ratio (INR) may shift either way (levonorgestrel/ethinylestradiol SmPC, AEMPS). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Ethinylestradiol + Levonorgestrel →

ModerateEthinylestradiol + NorgestimateCOC with norgestimate

Mechanism

Acenocoumarol is a vitamin K antagonist: it reduces the formation of the vitamin K-dependent clotting factors II, VII, IX and X (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its anticoagulant effect but gives no mechanism for them. As general routes of coumarin interactions, it names impaired absorption, inhibition or induction of liver enzymes, mainly CYP2C9, and reduced availability of vitamin K (acenocoumarol SmPC, AEMPS). Combined hormonal contraceptives raise the risk of venous thromboembolism compared with non-use. Epidemiological studies also link them to a higher risk of arterial thromboembolism, including myocardial infarction and stroke. Coagulation and fibrinolysis parameters can change, usually within the normal range (norgestimate/ethinylestradiol SmPC, AEMPS).

Symptoms

The anticoagulant effect of acenocoumarol can decrease. The international normalised ratio (INR) then falls below the target range, and protection against clots, the reason for acenocoumarol treatment, weakens (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The contraceptive itself raises the risk of thrombosis. Its SmPC lists signs that need urgent medical help: swelling and pain in one leg, sudden breathlessness, sharp chest pain, sudden numbness or weakness of the face, arm or leg, especially on one side, and difficulty speaking (norgestimate/ethinylestradiol SmPC, AEMPS). After the contraceptive is stopped, the effect of acenocoumarol can increase again, especially if its dose had been raised. With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).

Management

The combination itself is not contraindicated. However, section 4.3 of the norgestimate/ethinylestradiol summary of product characteristics (SmPC) rules out a combined hormonal contraceptive in current or past venous thromboembolism, for example deep vein thrombosis or pulmonary embolism. This applies even when current venous thromboembolism is treated with anticoagulants. If such a condition first appears during use, stop the contraceptive at once. So if acenocoumarol is prescribed for venous thromboembolism, the contraceptive is contraindicated (norgestimate/ethinylestradiol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The same SmPC contraindicates the contraceptive in current or past arterial thromboembolism, for example myocardial infarction, and in current or past stroke. It is also contraindicated in known predisposition to arterial thromboembolism, such as antiphospholipid antibodies. The SmPC lists valvular heart disease and atrial fibrillation among risk factors for arterial thromboembolism. With several risk factors or one severe risk factor, the contraceptive is contraindicated (norgestimate/ethinylestradiol SmPC, AEMPS). The indications of acenocoumarol include atrial fibrillation, the period after myocardial infarction, rheumatic mitral valve disease, prosthetic heart valves and antiphospholipid syndrome (acenocoumarol SmPC, AEMPS). The US label contraindicates norgestimate/ethinylestradiol in women at high risk of arterial or venous thrombotic disease. Examples include current or past deep vein thrombosis or pulmonary embolism and thrombogenic valvular or rhythm disease of the heart, such as atrial fibrillation (norgestimate/ethinylestradiol prescribing information, US Food and Drug Administration, ). Acenocoumarol is contraindicated in pregnancy, and women of childbearing potential must use effective contraception during treatment (acenocoumarol SmPC, AEMPS). The acenocoumarol SmPC lists oral contraceptives among the drugs that can reduce its effect. It asks for close and frequent coagulation checks, for example twice a week, when such a drug is added or stopped. A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. Base dose adjustments on the total weekly dose (acenocoumarol SmPCs, AEMPS). With an international normalised ratio (INR) of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Ethinylestradiol + Norgestimate →

ModerateFluconazoleAntifungals, triazole derivatives

Mechanism

In the liver, CYP2C9 is the main enzyme that metabolises acenocoumarol, and CYP1A2 and CYP2C19 also metabolise its more active R-enantiomer (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Fluconazole moderately inhibits CYP2C9 and CYP3A4 and strongly inhibits CYP2C19. Because of its long half-life, its effect on these enzymes persists for 4–5 days after fluconazole is stopped (fluconazole SmPC, AEMPS). The Spanish SmPC of a generic acenocoumarol explicitly names fluconazole among drugs that can potentiate acenocoumarol (acenocoumarol SmPC, AEMPS). The documents give no figures for acenocoumarol, and data exist only for warfarin. With warfarin plus fluconazole, the prothrombin time lengthened up to 2-fold, probably because fluconazole inhibits warfarin metabolism through CYP2C9 (fluconazole SmPC, AEMPS).

Symptoms

The main risk is bleeding. With fluconazole and warfarin, post-marketing reports described bleeding with a prolonged prothrombin time: bruising, nosebleeds, gastrointestinal bleeding, blood in the urine and black stools (fluconazole summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. When combining fluconazole with coumarin-type anticoagulants, which include acenocoumarol, monitor the prothrombin time carefully (fluconazole summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; fluconazole prescribing information, US Food and Drug Administration, ). These labels discuss dose adjustment only for warfarin. The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week, both when another drug is added and when it is stopped (acenocoumarol SmPCs, AEMPS). The effect of fluconazole on the enzymes persists for 4–5 days after fluconazole is stopped (fluconazole SmPC, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).

Pair details →Fluconazole →

ModerateFluorouracilAntineoplastic, pyrimidine analogue (5-FU)

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist. Liver enzymes, mainly CYP2C9, metabolise it. According to the Spanish generic acenocoumarol summary of product characteristics (SmPC), CYP2C9 inhibitors can potentiate its anticoagulant effect (acenocoumarol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). In a small number of patients stabilised on warfarin, marked rises in the prothrombin time and the international normalised ratio (INR) have been reported after fluorouracil was started. The Spanish fluorouracil SmPC extends regular monitoring of the anticoagulant response to other coumarin anticoagulants, and acenocoumarol is one of them (fluorouracil and acenocoumarol SmPCs, AEMPS). The documents do not describe the mechanism for this pair. For phenytoin, which CYP2C9 also metabolises, the fluorouracil SmPC presumes that fluorouracil inhibits CYP2C9 or CYP2C19. No formal interaction studies have been done (fluorouracil SmPC, AEMPS). According to the US fluorouracil label, altered coagulation parameters and bleeding, including deaths, have been reported with warfarin. The documents contain no study with acenocoumarol (fluorouracil prescribing information, US Food and Drug Administration, ).

Symptoms

The main risk is bleeding. After fluorouracil was started, marked rises in the prothrombin time and the international normalised ratio (INR) have been reported in patients stabilised on warfarin (fluorouracil summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label reports bleeding with this combination, including fatal cases (fluorouracil prescribing information, US Food and Drug Administration, ). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Cancer is one of the risk factors for bleeding during acenocoumarol treatment (acenocoumarol SmPC, AEMPS). Fluorouracil itself can cause bone marrow suppression, including thrombocytopenia, and gastrointestinal bleeding (fluorouracil SmPC, AEMPS).

Management

The combination is not contraindicated but needs regular coagulation monitoring. Monitor the response to coumarin anticoagulants regularly in patients receiving fluorouracil (fluorouracil summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPC asks for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added and when it is stopped (acenocoumarol SmPC, AEMPS). For warfarin, the US fluorouracil label asks for more frequent international normalised ratio (INR) checks and warfarin dose adjustment, including after fluorouracil is stopped (fluorouracil prescribing information, US Food and Drug Administration, ). During fluorouracil treatment, the SmPC recommends daily platelet and white cell counts. Stop fluorouracil if platelets fall below 100,000/mm³ and at the first sign of gastrointestinal bleeding or bleeding at any site (fluorouracil SmPC, AEMPS). Acenocoumarol is contraindicated with a platelet count below 50×10⁹/L (acenocoumarol SmPC, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Fluorouracil →

ModerateFluoxetineSelective serotonin reuptake inhibitors

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs list fluoxetine among the selective serotonin reuptake inhibitors (SSRIs) that can potentiate its anticoagulant effect (AEMPS). The Spanish fluoxetine SmPC groups oral anticoagulants with drugs that affect haemostasis and warns of a higher risk of bleeding in combination. According to the US label, serotonin release by platelets plays an important role in haemostasis. SSRIs, fluoxetine included, may raise the risk of bleeding on their own (fluoxetine SmPC, AEMPS; fluoxetine prescribing information, US Food and Drug Administration, ). Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs are given with warfarin. Fluoxetine is also tightly bound to plasma proteins, and with other tightly bound drugs a shift in plasma concentrations may cause adverse effects (fluoxetine prescribing information, FDA). Fluoxetine and its active metabolite norfluoxetine are eliminated slowly, with half-lives of 4–6 and 4–16 days. Fluoxetine stays in the body for 5–6 weeks after it is stopped (fluoxetine SmPC, AEMPS).

Symptoms

The main risk is bleeding. Bruising is uncommon with fluoxetine, and other bleeding, such as gynaecological, gastrointestinal, skin or mucosal bleeding, has been reported rarely (fluoxetine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the US label, bleeding with selective serotonin reuptake inhibitors ranges from ecchymoses, haematomas, nosebleeds and petechiae to life-threatening haemorrhage (fluoxetine prescribing information, US Food and Drug Administration, ). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. With oral anticoagulants, check the international normalised ratio (INR) more often. It may be appropriate to adjust the anticoagulant dose both during fluoxetine treatment and after it is stopped. Take the long elimination of fluoxetine and norfluoxetine into account: the drug stays in the body for 5–6 weeks after it is stopped (fluoxetine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when fluoxetine is added and when it is stopped (acenocoumarol SmPCs, AEMPS). The Spanish fluoxetine SmPC recommends caution with oral anticoagulants. The US label says to inform patients of the increased risk of bleeding (fluoxetine SmPC, AEMPS; fluoxetine prescribing information, US Food and Drug Administration, ). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).

Pair details →Fluoxetine →

ModerateGlucosamineAminomonosaccharide; in Spain glucosamine sulphate is registered as a prescription medicine for knee osteoarthritis, supplements more often contain the hydrochloride; marketed as a chondroprotective agent

Mechanism

The acenocoumarol and glucosamine summaries of product characteristics (SmPCs) report a raised international normalised ratio (INR) in people taking glucosamine with oral vitamin K antagonists (acenocoumarol and glucosamine SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol is a vitamin K antagonist (acenocoumarol SmPC, AEMPS). The documents do not describe the mechanism. Data on glucosamine interactions are limited. The absorption, distribution, metabolism and excretion of glucosamine are not fully understood, and its mechanism of action in humans is unknown (glucosamine SmPC, AEMPS).

Symptoms

The main risk is bleeding from a rise in the international normalised ratio (INR), which has been reported with glucosamine and vitamin K antagonists (acenocoumarol and glucosamine summaries of product characteristics, SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS). Tachycardia, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain can also occur (acenocoumarol SmPC, AEMPS).

Management

The combination is not contraindicated but needs close coagulation monitoring. In patients taking acenocoumarol, monitor coagulation closely when glucosamine is started and when it is stopped (acenocoumarol and glucosamine summaries of product characteristics, SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). Whenever any drug is added or stopped, use close and frequent coagulation checks, for example twice a week (acenocoumarol SmPC, AEMPS). Glucosamine is not indicated for acute pain. Relief usually appears within the first 4 weeks. If there is none after 2–3 months, reconsider continuing glucosamine (glucosamine SmPC, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose of acenocoumarol is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (acenocoumarol SmPC, AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. Restart acenocoumarol once the INR is back in the target range (acenocoumarol SmPC, AEMPS).

Pair details →Glucosamine →

ModerateLevofloxacinThird-generation fluoroquinolone

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist, and both the originator and the generic SmPC list fluoroquinolones among the drugs that can potentiate its effect (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The documents do not explain how levofloxacin potentiates the anticoagulant. Levofloxacin does not inhibit CYP1A2, one of the enzymes that metabolise the more active R-enantiomer of acenocoumarol (levofloxacin and acenocoumarol SmPCs, AEMPS). In healthy volunteers it did not change the concentrations or disposition of R- and S-warfarin (levofloxacin prescribing information, US Food and Drug Administration, ). Even so, post-marketing reports describe levofloxacin potentiating the effect of warfarin, with raised prothrombin times accompanied by bleeding. Data exist only for warfarin (FDA). Infection and inflammation can reduce the protein binding of acenocoumarol, so strict medical supervision is needed during such periods (acenocoumarol SmPC, AEMPS).

Symptoms

The main risk is bleeding. With levofloxacin and a vitamin K antagonist such as warfarin, reports describe a raised prothrombin time and international normalised ratio (INR) and bleeding, which may be serious (levofloxacin summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an INR above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. When levofloxacin is combined with a vitamin K antagonist, acenocoumarol included, check the prothrombin time and the international normalised ratio (INR) (levofloxacin summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US levofloxacin label refers only to warfarin and asks for close monitoring of these tests and of signs of bleeding (levofloxacin prescribing information, US Food and Drug Administration, ). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added and when it is stopped, including after the end of a levofloxacin course (acenocoumarol SmPCs, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).

Pair details →Levofloxacin →

ModerateLevonorgestrelProgestogen-only contraceptive (POP + emergency contraception)

Mechanism

Acenocoumarol is a vitamin K antagonist: it reduces the formation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs list oral contraceptives among the drugs that can reduce its anticoagulant effect, without giving a mechanism (acenocoumarol SmPCs, AEMPS). In Spain, levonorgestrel tablets without an oestrogen are available only for emergency contraception, as a single 1.5 mg tablet by mouth. Their SmPCs call this oral emergency contraception (levonorgestrel SmPCs, AEMPS). The documents contain no study of this pair. According to the levonorgestrel SmPC, no significant changes in clotting factors are expected at the recommended dose (levonorgestrel SmPC, AEMPS).

Symptoms

According to the acenocoumarol summary of product characteristics (SmPC), oral contraceptives can reduce the effect of acenocoumarol. The international normalised ratio (INR) then falls below the target range, and protection against clots, the reason for acenocoumarol treatment, weakens (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). After a 1.5 mg levonorgestrel tablet, heavy periods and bleeding are very common. Spotting and irregular bleeding have been reported in up to 30% of women until the next period. Post-marketing reports include isolated thromboembolic events (levonorgestrel SmPC, AEMPS). Uterine bleeding is also among the signs of excess acenocoumarol, together with bleeding into the skin, blood in the urine, bruising, and gastrointestinal, nose and gum bleeding (acenocoumarol SmPC, AEMPS).

Management

The combination is not contraindicated. The acenocoumarol summary of product characteristics (SmPC) lists oral contraceptives among the drugs that can reduce its effect. The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when such a drug is added and when it is stopped (acenocoumarol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol is contraindicated in pregnancy, and women of childbearing potential need effective contraception during treatment (acenocoumarol SmPC, AEMPS). Emergency contraception does not prevent pregnancy in every case and does not replace a regular method. If the period is more than 5 days late or the bleeding at the expected time is unusual, rule out pregnancy with a test (levonorgestrel SmPC, AEMPS). Use a barrier method until the next menstrual cycle starts. Repeated use within one cycle is not recommended (levonorgestrel SmPC, AEMPS). Consider the possibility of thromboembolism in women with other thromboembolic risk factors, especially a personal or family history suggesting thrombophilia (levonorgestrel SmPC, AEMPS). With an international normalised ratio (INR) of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Levonorgestrel →

ModerateLevothyroxine sodiumThyroid hormones

Mechanism

Levothyroxine displaces anticoagulants from their binding to plasma proteins, so the effect of coumarins can increase (levothyroxine summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol is 98.7% bound to plasma proteins, mainly albumin, and both the originator and the generic SmPC list thyroid hormones among the drugs that can potentiate it (acenocoumarol SmPCs, AEMPS). According to the US label, levothyroxine increases the response to oral anticoagulant therapy (levothyroxine prescribing information, US Food and Drug Administration, ). Thyrotoxicosis can also reduce the protein binding of acenocoumarol, so strict medical supervision is needed in this condition (acenocoumarol SmPC, AEMPS).

Symptoms

The main risk is bleeding. When levothyroxine intensifies the anticoagulant effect, the risk of bleeding rises, for example bleeding in the central nervous system or gastrointestinal bleeding, especially in older people (levothyroxine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. Check coagulation parameters regularly at the start of and during combined treatment, and reduce the anticoagulant dose if needed (levothyroxine summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the US label, the anticoagulant dose may need to be lowered when hypothyroidism is corrected or the levothyroxine dose is increased. Monitor coagulation tests closely so that the dose can be adjusted in time (levothyroxine prescribing information, US Food and Drug Administration, ). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added and when it is stopped (acenocoumarol SmPCs, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (AEMPS). With an international normalised ratio (INR) below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).

Pair details →Levothyroxine sodium →

ModerateMetronidazoleImidazole derivatives (antiprotozoal / antibacterial)

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the Spanish metronidazole SmPCs, metronidazole can potentiate coumarin-type anticoagulants, acenocoumarol included, and raise the risk of bleeding because it slows their breakdown in the liver. The SmPCs do not name the enzyme involved (metronidazole SmPCs, AEMPS). The acenocoumarol SmPC names metronidazole among the imidazole derivatives that can potentiate acenocoumarol, and the generic SmPC lists it among antibiotics with the same effect (AEMPS). The US label states that metronidazole has been reported to potentiate warfarin and other oral coumarin anticoagulants and to prolong the prothrombin time (metronidazole prescribing information, US Food and Drug Administration, ). Infection and inflammation can reduce the protein binding of acenocoumarol, so strict medical supervision is needed during such periods (acenocoumarol SmPC, AEMPS).

Symptoms

The main risk is bleeding. The Spanish metronidazole SmPCs describe a higher risk of bleeding with coumarin-type anticoagulants, and the US label reports a prolonged prothrombin time (metronidazole summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; metronidazole prescribing information, US Food and Drug Administration, ). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. During metronidazole treatment, check the prothrombin time frequently and adjust the anticoagulant dose (metronidazole summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label asks for careful monitoring of the prothrombin time and the international normalised ratio (INR) (metronidazole prescribing information, US Food and Drug Administration, ). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added and when it is stopped, including after the end of the antibiotic course (acenocoumarol SmPCs, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).

Pair details →Metronidazole →

ModerateMiconazoleImidazole antifungal

Mechanism

Miconazole inhibits the enzymes CYP2C9 and CYP3A4 (miconazole oral gel summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and CYP2C9 is the main enzyme that metabolises acenocoumarol (acenocoumarol SmPC, AEMPS). The acenocoumarol SmPC lists miconazole among the imidazole derivatives that can potentiate acenocoumarol, including miconazole applied locally (AEMPS). The size of the effect depends on how much miconazole reaches the blood. Miconazole from the oral gel is absorbed: after 60 mg, peak plasma levels are 31–49 ng/mL and the half-life is 20–25 hours (oral gel SmPC, AEMPS). From a cream, less than 1% of the dose is absorbed (miconazole cream SmPC, AEMPS). The Spanish miconazole vaginal ovules also contain metronidazole, and the acenocoumarol SmPC lists metronidazole among the drugs that potentiate acenocoumarol as well (vaginal ovule SmPC; acenocoumarol SmPC, AEMPS).

Symptoms

The main risk is bleeding. Data exist only for warfarin. With miconazole oral gel, bleeding events have been reported, some of them fatal (miconazole oral gel summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Bleeding and bruising have also been reported after topical, vaginal and oral miconazole (miconazole buccal tablet prescribing information, US Food and Drug Administration, ). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. The miconazole oral gel SmPC contraindicates the gel only with warfarin. It lists acenocoumarol among the oral anticoagulants that need caution with the gel: monitor the prothrombin time or other suitable anticoagulation tests closely and adjust the anticoagulant dose (miconazole oral gel summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Use miconazole creams and vaginal ovules cautiously with vitamin K antagonists, which include acenocoumarol. Monitor the anticoagulant effect carefully and titrate the dose. Explain the signs of bleeding to the patient and ask them to stop miconazole at once if these appear (miconazole cream and vaginal ovule SmPCs, AEMPS). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week, both when another drug is added and when it is stopped (acenocoumarol SmPCs, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).

Pair details →Miconazole →

ModerateOmeprazoleProton pump inhibitors

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist. The Spanish acenocoumarol SmPCs, both the originator and a generic, list proton pump inhibitors, for example omeprazole, among drugs that can potentiate its anticoagulant effect (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In the liver, CYP2C9 is the main enzyme that metabolises acenocoumarol, and CYP1A2 and CYP2C19 also metabolise its R-enantiomer, which has a much stronger anticoagulant effect (acenocoumarol SmPC, AEMPS). Omeprazole is a moderate CYP2C19 inhibitor, so it can slow the metabolism of other drugs that this enzyme metabolises and raise their levels. The omeprazole SmPC gives D-warfarin and other vitamin K antagonists as examples (omeprazole SmPC, AEMPS). For warfarin, the US omeprazole label reports increased international normalised ratio (INR) and prothrombin time in people taking warfarin with proton pump inhibitors, including omeprazole (omeprazole prescribing information, US Food and Drug Administration, ). The documents do not say how much the INR changes when omeprazole is combined with acenocoumarol.

Symptoms

For warfarin, the US omeprazole label states that increases in the international normalised ratio (INR) and prothrombin time may lead to abnormal bleeding and even death (omeprazole prescribing information, US Food and Drug Administration, ). Acenocoumarol can cause serious or fatal bleeding, including haemorrhagic shock. The risk is higher with an INR above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints, as well as fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain (acenocoumarol SmPC, AEMPS).

Management

No document contraindicates or prohibits this combination. When omeprazole is started or stopped, consider possible interactions with drugs metabolised by CYP2C19 (omeprazole summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week, both when omeprazole is added and when it is stopped (acenocoumarol SmPCs, AEMPS). For warfarin, the US omeprazole label advises monitoring the international normalised ratio (INR) and prothrombin time and adjusting the warfarin dose if needed to keep the INR in the target range (omeprazole prescribing information, US Food and Drug Administration, ). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt it and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Omeprazole →

ModerateParacetamolAnilides. Analgesics and antipyretics

Mechanism

Acenocoumarol is a vitamin K antagonist. The Spanish acenocoumarol SmPCs, both the originator and a generic, list paracetamol among drugs that can potentiate its anticoagulant effect (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the paracetamol SmPCs, chronic use of paracetamol at doses above 2 g a day may increase the effect of the oral anticoagulants acenocoumarol and warfarin. This may happen because the liver makes fewer clotting factors (paracetamol SmPC, AEMPS). At doses below 2 g a day the effect appears to be of little clinical relevance (paracetamol SmPC, AEMPS). The documents do not say how much the international normalised ratio (INR) rises.

Symptoms

The main risk is bleeding. Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS). Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow, and laboratory tests show a very high INR (AEMPS).

Management

The documents neither contraindicate nor prohibit this combination. In people taking anticoagulants, paracetamol is considered an alternative to salicylates (paracetamol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). When paracetamol is added to acenocoumarol or stopped, use close and frequent coagulation checks, for example twice a week (acenocoumarol SmPCs, AEMPS). The effect of acenocoumarol may increase with chronic use of paracetamol at doses above 2 g a day. At lower doses, the effect appears to be of little clinical relevance (paracetamol SmPC, AEMPS). This 2 g threshold is below the usual adult maximum of 4 g of paracetamol a day. People with chronic alcohol misuse should not take more than 2 g a day (paracetamol SmPC, AEMPS). With an international normalised ratio (INR) of 4.5–10 and no significant bleeding, interrupt acenocoumarol. In significant bleeding, interrupt it and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Paracetamol →

ModeratePhenobarbitalAntiepileptics. Barbiturates

Mechanism

Liver enzymes, mainly CYP2C9, metabolise acenocoumarol, and inducers of CYP2C9, CYP2C19 and CYP3A4 can reduce its anticoagulant effect (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Phenobarbital is a potent inducer of drug-metabolising enzymes (cytochrome P450 enzymes and UDP-glycosyltransferases) and can speed up the metabolism of many drugs and reduce their efficacy. According to the Spanish phenobarbital SmPC, the efficacy of oral anticoagulants decreases (phenobarbital SmPC, AEMPS). The US phenobarbital label names acenocoumarol explicitly. Barbiturates can induce liver enzymes, so oral anticoagulants such as acenocoumarol, warfarin, dicoumarol and phenprocoumon are metabolised faster and their anticoagulant response decreases (phenobarbital prescribing information, US Food and Drug Administration, ). The acenocoumarol SmPC also lists barbiturates, for example phenobarbital, among drugs that can reduce its effect (acenocoumarol SmPC, AEMPS).

Symptoms

The anticoagulant effect of acenocoumarol decreases (phenobarbital summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The international normalised ratio (INR) then falls below the target range, and protection against clots, the reason for acenocoumarol treatment, weakens. After phenobarbital is stopped, the effect of acenocoumarol can increase again, especially if its dose was raised. With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).

Management

The combination is not contraindicated but needs close coagulation monitoring. The Spanish phenobarbital summary of product characteristics (SmPC) places oral anticoagulants among combinations that call for caution, clinical monitoring and/or dose adjustment. During combined treatment, check the prothrombin time and the international normalised ratio (INR) frequently. Adjust the anticoagulant dose throughout phenobarbital treatment and for 8 days after it is stopped (phenobarbital SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPC lists barbiturates such as phenobarbital among drugs that need close and frequent coagulation checks, for example twice a week, both when they are added and when they are stopped (acenocoumarol SmPC, AEMPS). According to the US phenobarbital label, patients stabilised on anticoagulant therapy may need dose adjustment when a barbiturate is added or withdrawn (phenobarbital prescribing information, US Food and Drug Administration, ). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Phenobarbital →

ModeratePhenytoinAntiepileptic, hydantoin derivative (sodium channel blocker)

Mechanism

Liver enzymes, mainly CYP2C9, metabolise acenocoumarol, and inducers of CYP2C9, CYP2C19 and CYP3A4 can reduce its anticoagulant effect (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Phenytoin is a strong inducer of liver enzymes that metabolise drugs. The Spanish phenytoin SmPCs list oral anticoagulants among the drugs whose levels or effect it can alter or reduce, although acenocoumarol is not among the examples (phenytoin SmPCs, AEMPS; phenytoin prescribing information, US Food and Drug Administration, ). According to the acenocoumarol SmPC, serum phenytoin levels can rise during concomitant treatment. The SmPC does not give the mechanism (acenocoumarol SmPC, AEMPS). CYP2C9 is the main enzyme that metabolises phenytoin. This metabolism is saturable, and its inhibition can raise phenytoin levels considerably (phenytoin SmPC, AEMPS). The documents contain no study with acenocoumarol. For warfarin, the US phenytoin label reports both increased and decreased international normalised ratio (INR) responses. It also lists warfarin among the drugs that raise phenytoin levels (phenytoin prescribing information, FDA).

Symptoms

The anticoagulant effect of acenocoumarol can decrease. The international normalised ratio (INR) then falls below the target range, and protection against clots, the reason for acenocoumarol treatment, weakens (acenocoumarol and phenytoin summaries of product characteristics, SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). For warfarin, the US phenytoin label reports INR shifts in both directions (phenytoin prescribing information, US Food and Drug Administration, ). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS). When phenytoin levels rise, the first signs are nystagmus, loss of coordination (ataxia) and slurred speech. Tremor, drowsiness, blurred vision, nausea and vomiting follow (phenytoin SmPC, overdose section, AEMPS). Phenytoin levels above the optimal range can cause confusion (phenytoin SmPC, AEMPS).

Management

The combination is not contraindicated but needs close monitoring of coagulation and of phenytoin levels. The acenocoumarol summary of product characteristics (SmPC) asks for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added to acenocoumarol and when it is stopped (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Measure serum phenytoin levels when an interaction is suspected (phenytoin SmPCs, AEMPS; phenytoin prescribing information, US Food and Drug Administration, ). When needed, check them 7–10 days after another drug is added or stopped, once the new steady state is reached. Most patients have optimal seizure control without signs of toxicity at 10–20 micrograms/ml (phenytoin SmPC, AEMPS). At the first sign of phenytoin toxicity, measure its level and reduce the dose if the level is high (phenytoin SmPC, AEMPS). For warfarin, the US phenytoin label states that adding or stopping phenytoin may require a change in the warfarin dose (phenytoin prescribing information, FDA). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Phenytoin →

ModeratePrednisoneShort-to-medium acting systemic glucocorticoid

Mechanism

The acenocoumarol summary of product characteristics (SmPC) lists corticosteroids, including methylprednisolone and prednisone, among drugs that can potentiate the anticoagulant effect of acenocoumarol (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the prednisone SmPC, the anticoagulant effect of coumarin derivatives, which include acenocoumarol, can either decrease or increase (prednisone SmPC, AEMPS). The US prednisone label gives data for warfarin only: the response to warfarin usually weakens, although some reports conflict (prednisone prescribing information, US Food and Drug Administration, ). Prednisone itself can cause peptic ulcers and gastrointestinal bleeding (prednisone SmPC, AEMPS), and peptic ulcer and gastrointestinal bleeding are contraindications to acenocoumarol (acenocoumarol SmPC, AEMPS).

Symptoms

The anticoagulant effect of acenocoumarol can either increase or decrease (prednisone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), so the international normalised ratio (INR) can move in either direction. When the INR rises, the main risk is bleeding. With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS). When the INR falls below the target range, protection against clots, the reason for acenocoumarol treatment, weakens. Prednisone itself can cause peptic ulcers and gastrointestinal bleeding (prednisone SmPC, AEMPS).

Management

The combination is not contraindicated but needs close coagulation monitoring. Among corticosteroids, the acenocoumarol summary of product characteristics (SmPC) places only high intravenous doses of methylprednisolone among combinations that are generally not recommended. Prednisone is on the list of drugs that need close and frequent coagulation checks, for example twice a week, both when they are added and when they are stopped (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). When prednisone is given with coumarin derivatives, the anticoagulant dose may need adjusting (prednisone SmPC, AEMPS). For warfarin, the US prednisone label asks for frequent monitoring of coagulation indices to keep the desired anticoagulant effect (prednisone prescribing information, US Food and Drug Administration, ). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose of acenocoumarol is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (acenocoumarol SmPC, AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. Restart acenocoumarol once the INR is back in the target range (acenocoumarol SmPC, AEMPS).

Pair details →Prednisone →

ModerateRifampicinAntituberculous antibiotic

Mechanism

Liver enzymes, mainly CYP2C9, metabolise acenocoumarol, and inducers of CYP2C9, CYP2C19 and CYP3A4 can reduce its anticoagulant effect (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Rifampicin is a potent inducer of drug-metabolising enzymes, including CYP1A2, CYP2C9, CYP2C19 and CYP3A4, and can speed up the metabolism of other drugs and reduce their effect (rifampicin SmPC, AEMPS). The acenocoumarol SmPC names rifampicin among the drugs that can reduce the anticoagulant effect of acenocoumarol (acenocoumarol SmPC, AEMPS). The documents do not say how much acenocoumarol levels fall. Data exist only for warfarin: rifampicin 600 mg daily reduced the area under the concentration–time curve (AUC) of S-warfarin by 74% (rifampicin SmPC, AEMPS). Rifampicin itself can cause vitamin K-dependent coagulation disorders and severe bleeding (rifampicin SmPC, AEMPS).

Symptoms

The anticoagulant effect of acenocoumarol can weaken: the international normalised ratio (INR) falls below the target range, and protection against clots, the reason for acenocoumarol treatment, weakens (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). At the same time, rifampicin itself can cause vitamin K-dependent coagulation disorders and severe bleeding (rifampicin SmPC, AEMPS). After rifampicin is stopped, the effect of acenocoumarol can increase again, especially if its dose was raised. With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).

Management

The combination is not contraindicated but needs close coagulation monitoring. The acenocoumarol summary of product characteristics (SmPC) lists rifampicin among drugs that can reduce its effect. It asks for close and frequent coagulation checks, for example twice a week, both when such a drug is added and when it is stopped (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In the Spanish rifampicin SmPCs, anticoagulants, including coumarins, are among the drugs affected by rifampicin, and their dose may need adjustment when rifampicin is started or stopped (rifampicin SmPCs, AEMPS). The US rifampicin label says to measure the prothrombin time daily or as often as needed to establish and maintain the required dose of an oral anticoagulant (rifampicin prescribing information, US Food and Drug Administration, ). In people at risk of vitamin K deficiency, including those on long-term anticoagulants, monitor the prothrombin time and other coagulation tests during rifampicin treatment. If the tests are abnormal or bleeding occurs, consider stopping rifampicin (rifampicin prescribing information, FDA). The Spanish SmPC advises watching for coagulopathy in people at particular risk of bleeding (rifampicin SmPC, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Rifampicin →

ModerateRitonavirHIV protease inhibitor / pharmacokinetic booster

Mechanism

Liver enzymes, mainly CYP2C9, metabolise acenocoumarol, and CYP1A2 and CYP2C19 also take part in breaking down its R-enantiomer (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Ritonavir can induce CYP1A2, CYP2C8, CYP2C9 and CYP2C19 and lower the levels of drugs that these enzymes metabolise (ritonavir SmPC, European Medicines Agency, ). The acenocoumarol SmPC lists human immunodeficiency virus (HIV) protease inhibitors, including ritonavir, among drugs that can reduce its anticoagulant effect (AEMPS). The documents do not say how much acenocoumarol levels fall. Data exist only for warfarin. Ritonavir 400 mg twice daily reduced the area under the concentration–time curve (AUC) of R-warfarin by 33% and had only a slight effect on S-warfarin (ritonavir SmPC, EMA, and label, US Food and Drug Administration, ).

Symptoms

The anticoagulant effect of acenocoumarol can decrease. The international normalised ratio (INR) then falls below the target range, and protection against clots, the reason for acenocoumarol treatment, weakens (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the US ritonavir label, warfarin levels can change in either direction (ritonavir label, US Food and Drug Administration, ). After ritonavir is stopped, the effect of acenocoumarol can change again (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).

Management

The combination is not contraindicated but needs close coagulation monitoring. The acenocoumarol summary of product characteristics (SmPC) lists ritonavir among drugs that can reduce its effect. The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when such a drug is added and when it is stopped (acenocoumarol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The ritonavir documents have no separate entry for acenocoumarol. For warfarin, the European ritonavir SmPC recommends monitoring anticoagulation parameters both at antiretroviral doses of ritonavir and at the low dose used to boost other protease inhibitors. The US ritonavir label recommends frequent international normalised ratio (INR) checks at the start of co-administration (ritonavir SmPC, European Medicines Agency, , and label, US Food and Drug Administration, ). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose (acenocoumarol SmPC, AEMPS). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Ritonavir →

ModerateSertralineSelective serotonin reuptake inhibitors (SSRIs)

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs list sertraline among the selective serotonin reuptake inhibitors (SSRIs) that can potentiate its anticoagulant effect (AEMPS). SSRIs, sertraline included, raise the risk of bleeding on their own, and anticoagulants may add to this risk (sertraline SmPC, AEMPS; sertraline prescribing information, US Food and Drug Administration, ). The sertraline labels describe a combination study only with warfarin. Sertraline 200 mg a day caused a small but statistically significant prolongation of the prothrombin time, which in rare cases can change the INR (sertraline SmPC, AEMPS). CYP2C9 is the main enzyme in acenocoumarol metabolism, and according to its Spanish SmPC sertraline does not inhibit CYP2C9, CYP2C19 or CYP1A2 to a clinically significant degree (acenocoumarol and sertraline SmPCs, AEMPS).

Symptoms

The main risk is bleeding. Abnormal bleeding has been reported with selective serotonin reuptake inhibitors (SSRIs), sertraline included: bleeding into the skin (ecchymosis and purpura), gastrointestinal and gynaecological bleeding, including fatal bleeding (sertraline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the US label, such bleeding ranges from ecchymoses, haematomas, nosebleeds and petechiae to life-threatening haemorrhage (sertraline prescribing information, US Food and Drug Administration, ). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. The acenocoumarol summaries of product characteristics (SmPC) ask for close and frequent coagulation checks, for example twice a week. This applies both when sertraline is added and when it is stopped (acenocoumarol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish sertraline SmPC asks for caution when sertraline is combined with anticoagulants and in patients with a history of bleeding disorders. The US label says to inform patients of the increased risk of bleeding (sertraline SmPC, AEMPS; sertraline prescribing information, US Food and Drug Administration, ). Acenocoumarol is 98.7% bound to plasma proteins. With such highly bound drugs, monitor for adverse reactions and reduce the dose of sertraline or of the other drug as warranted (sertraline prescribing information, FDA; acenocoumarol SmPC, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).

Pair details →Sertraline →

ModerateSimvastatinHMG-CoA reductase inhibitors (statins)

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist. The Spanish acenocoumarol SmPCs, both the originator and a generic, list simvastatin among statins that can potentiate its anticoagulant effect (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The documents do not say how simvastatin produces this effect (AEMPS). According to the simvastatin labels, in two clinical studies simvastatin 20–40 mg a day modestly potentiated the effect of coumarin anticoagulants. The international normalised ratio (INR) rose from 1.7 to 1.8 in healthy volunteers and from 2.6 to 3.4 in patients with high cholesterol (simvastatin SmPC, AEMPS; simvastatin prescribing information, US Food and Drug Administration, ). The Spanish simvastatin SmPC also mentions rare cases of increased INR. In people not taking anticoagulants, simvastatin treatment has not been associated with bleeding or changes in prothrombin time (simvastatin SmPC, AEMPS).

Symptoms

According to the US simvastatin label, there are post-marketing reports of clinically evident bleeding or increased international normalised ratio (INR) in people taking statins together with warfarin (simvastatin prescribing information, US Food and Drug Administration, ). Acenocoumarol can cause serious or fatal bleeding, including haemorrhagic shock. The risk is higher with an INR above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints, as well as fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain (acenocoumarol SmPC, AEMPS).

Management

No document contraindicates or prohibits this combination, but coagulation is monitored when simvastatin is started. In people taking a coumarin anticoagulant, measure the prothrombin time and the international normalised ratio (INR) before starting simvastatin and frequently enough early in treatment to make sure there is no significant change. Once the value is stable, check it at the intervals usual for the anticoagulant (simvastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; simvastatin prescribing information, US Food and Drug Administration, ). Repeat the same steps if the simvastatin dose is changed or simvastatin is stopped (simvastatin SmPC and prescribing information, AEMPS and FDA). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week, both when simvastatin is added and when it is stopped (acenocoumarol SmPCs, AEMPS). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt it and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Pair details →Simvastatin →

ModerateTramadolOther opioids

Mechanism

In its list of pharmacokinetic interactions, the acenocoumarol summary of product characteristics (SmPC) names tramadol among drugs that can potentiate the anticoagulant effect of acenocoumarol. It does not explain the mechanism (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The tramadol SmPC reports cases of a raised international normalised ratio (INR) with major bleeding and ecchymosis when tramadol is combined with coumarin derivatives (tramadol SmPC, AEMPS). Acenocoumarol is a coumarin derivative (acenocoumarol SmPC, AEMPS). The US tramadol label has data for warfarin only: rare post-marketing reports of an altered warfarin effect, including prolonged prothrombin times (tramadol prescribing information, US Food and Drug Administration, ).

Symptoms

The main risk is bleeding from an excessive acenocoumarol effect. With coumarin derivatives, the tramadol summary of product characteristics (SmPC) reports cases of a raised international normalised ratio (INR) with major bleeding and ecchymosis (tramadol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS). Tachycardia, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain can also occur (acenocoumarol SmPC, AEMPS).

Management

The combination is not contraindicated but needs caution (tramadol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Close and frequent coagulation checks, for example twice a week, are needed both when tramadol is added to acenocoumarol and when it is stopped (acenocoumarol SmPC, AEMPS). For warfarin, the US tramadol label asks for frequent re-evaluation of the prothrombin time and warfarin dose adjustment as needed (tramadol prescribing information, US Food and Drug Administration, ). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose of acenocoumarol is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (acenocoumarol SmPC, AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. Restart acenocoumarol once the INR is back in the target range (acenocoumarol SmPC, AEMPS).

Pair details →Tramadol →

ModerateVoriconazoleTriazole derivatives, systemic antifungals

Mechanism

In the liver, CYP2C9 is the main enzyme that metabolises acenocoumarol, and CYP1A2 and CYP2C19 also metabolise its more active R-enantiomer (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Voriconazole inhibits CYP2C19, CYP2C9 and CYP3A4 (voriconazole SmPC, European Medicines Agency, ). The pair has not been studied, but both voriconazole labels expect levels of other coumarins, acenocoumarol included, to rise and the prothrombin time to lengthen (EMA; voriconazole prescribing information, US Food and Drug Administration, ). The only data are for warfarin: voriconazole 300 mg twice daily roughly doubled the maximum prothrombin time after a single 30 mg dose of warfarin (EMA; FDA).

Symptoms

The main risk is bleeding. Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS). Acute kidney injury may occur with excessive anticoagulation and blood in the urine, especially in people with previous kidney disease (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. The voriconazole labels name acenocoumarol among the coumarins that need close monitoring of the prothrombin time or other suitable anticoagulation tests, with anticoagulant dose adjustment (voriconazole summary of product characteristics, SmPC, European Medicines Agency, ; voriconazole prescribing information, US Food and Drug Administration, ). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added and when it is stopped, including after the end of a voriconazole course (acenocoumarol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days (AEMPS). Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (AEMPS). With an international normalised ratio (INR) below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).

Pair details →Voriconazole →

Label mentions68 mentions

Verbatim lines from the interaction sections, in the language of the label

From this drug’s label

  • «Heparina (excepto aquellas situaciones donde se requiera una rápida anticoagulación, ver sección 4.2.), inhibidores de la agregación plaquetaria tales como clopidogrel, ticlopidina o ácido salicílico…»

    AEMPS, section 4.5 · Open on CIMA

  • MajorAINEclass named in the label
    «Heparina (excepto aquellas situaciones donde se requiera una rápida anticoagulación, ver sección 4.2.), inhibidores de la agregación plaquetaria tales como clopidogrel, ticlopidina o ácido salicílico…»

    AEMPS, section 4.5 · Open on CIMA

  • Majorantiagregantesclass named in the label
    «Heparina (excepto aquellas situaciones donde se requiera una rápida anticoagulación, ver sección 4.2.), inhibidores de la agregación plaquetaria tales como clopidogrel, ticlopidina o ácido salicílico…»

    AEMPS, section 4.5 · Open on CIMA

  • «Heparina (excepto aquellas situaciones donde se requiera una rápida anticoagulación, ver sección 4.2.), inhibidores de la agregación plaquetaria tales como clopidogrel, ticlopidina o ácido salicílico…»

    AEMPS, section 4.5 · Open on CIMA

  • «Heparina (excepto aquellas situaciones donde se requiera una rápida anticoagulación, ver sección 4.2.), inhibidores de la agregación plaquetaria tales como clopidogrel, ticlopidina o ácido salicílico…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateAllopurinol
    «Los siguientes medicamentos pueden potenciar el efecto anticoagulante de acenocumarol : alopurinol, esteroides anabolizantes, andrógenos, agentes antiarrítmicos (p.ej. amiodarona, quinidina)…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateAmiodarone
    «Los siguientes medicamentos pueden potenciar el efecto anticoagulante de acenocumarol : alopurinol, esteroides anabolizantes, andrógenos, agentes antiarrítmicos (p.ej. amiodarona, quinidina)…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateAmoxicillin
    «Los siguientes medicamentos pueden potenciar el efecto anticoagulante de acenocumarol : alopurinol, esteroides anabolizantes, andrógenos, agentes antiarrítmicos (p.ej. amiodarona, quinidina)…»

    AEMPS, section 4.5 · Open on CIMA

  • Moderateantiácidosclass named in the label
    «Los siguientes medicamentos pueden potenciar el efecto anticoagulante de acenocumarol : alopurinol, esteroides anabolizantes, andrógenos, agentes antiarrítmicos (p.ej. amiodarona, quinidina)…»

    AEMPS, section 4.5 · Open on CIMA

  • Moderateantiarrítmicosclass named in the label
    «Los siguientes medicamentos pueden potenciar el efecto anticoagulante de acenocumarol : alopurinol, esteroides anabolizantes, andrógenos, agentes antiarrítmicos (p.ej. amiodarona, quinidina)…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateAtorvastatin
    «Los siguientes medicamentos pueden potenciar el efecto anticoagulante de acenocumarol : alopurinol, esteroides anabolizantes, andrógenos, agentes antiarrítmicos (p.ej. amiodarona, quinidina)…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateAzathioprine
    «Los siguientes medicamentos pueden disminuir el efecto anticoagulante de acenocumarol : aminoglutetimida, antineoplásicos (azatioprina, 6-mercaptopurina), barbitúricos (p. ej. fenobarbital)…»

    AEMPS, section 4.5 · Open on CIMA

  • Moderatebarbitúricosclass named in the label
    «Los siguientes medicamentos pueden disminuir el efecto anticoagulante de acenocumarol : aminoglutetimida, antineoplásicos (azatioprina, 6-mercaptopurina), barbitúricos (p. ej. fenobarbital)…»

    AEMPS, section 4.5 · Open on CIMA

  • «Los siguientes medicamentos pueden disminuir el efecto anticoagulante de acenocumarol : aminoglutetimida, antineoplásicos (azatioprina, 6-mercaptopurina), barbitúricos (p. ej. fenobarbital)…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateCisapride
    «Los siguientes medicamentos pueden potenciar el efecto anticoagulante de acenocumarol : alopurinol, esteroides anabolizantes, andrógenos, agentes antiarrítmicos (p.ej. amiodarona, quinidina)…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateCitalopram
    «Los siguientes medicamentos pueden potenciar el efecto anticoagulante de acenocumarol : alopurinol, esteroides anabolizantes, andrógenos, agentes antiarrítmicos (p.ej. amiodarona, quinidina)…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateClindamycin
    «Los siguientes medicamentos pueden potenciar el efecto anticoagulante de acenocumarol : alopurinol, esteroides anabolizantes, andrógenos, agentes antiarrítmicos (p.ej. amiodarona, quinidina)…»

    AEMPS, section 4.5 · Open on CIMA

  • Moderatecorticosteroidesclass named in the label
    «Los siguientes medicamentos pueden potenciar el efecto anticoagulante de acenocumarol : alopurinol, esteroides anabolizantes, andrógenos, agentes antiarrítmicos (p.ej. amiodarona, quinidina)…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateDisulfiram
    «Los siguientes medicamentos pueden potenciar el efecto anticoagulante de acenocumarol : alopurinol, esteroides anabolizantes, andrógenos, agentes antiarrítmicos (p.ej. amiodarona, quinidina)…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateErythromycin
    «Los siguientes medicamentos pueden potenciar el efecto anticoagulante de acenocumarol : alopurinol, esteroides anabolizantes, andrógenos, agentes antiarrítmicos (p.ej. amiodarona, quinidina)…»

    AEMPS, section 4.5 · Open on CIMA

  • Moderateestatinasclass named in the label
    «Los siguientes medicamentos pueden potenciar el efecto anticoagulante de acenocumarol : alopurinol, esteroides anabolizantes, andrógenos, agentes antiarrítmicos (p.ej. amiodarona, quinidina)…»

    AEMPS, section 4.5 · Open on CIMA

  • Moderatefibratosclass named in the label
    «Los siguientes medicamentos pueden potenciar el efecto anticoagulante de acenocumarol : alopurinol, esteroides anabolizantes, andrógenos, agentes antiarrítmicos (p.ej. amiodarona, quinidina)…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateFluoxetine
    «Los siguientes medicamentos pueden potenciar el efecto anticoagulante de acenocumarol : alopurinol, esteroides anabolizantes, andrógenos, agentes antiarrítmicos (p.ej. amiodarona, quinidina)…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateFluvastatin
    «Los siguientes medicamentos pueden potenciar el efecto anticoagulante de acenocumarol : alopurinol, esteroides anabolizantes, andrógenos, agentes antiarrítmicos (p.ej. amiodarona, quinidina)…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateGlucosamine
    «Se ha notificado un aumento del INR en pacientes que toman glucosamina y antagonistas orales de vitamina K. Por lo tanto, los pacientes tratados con antagonistas orales de la vitamina K deben ser…»

    AEMPS, section 4.5 · Open on CIMA

  • «Los siguientes medicamentos pueden disminuir el efecto anticoagulante de acenocumarol : aminoglutetimida, antineoplásicos (azatioprina, 6-mercaptopurina), barbitúricos (p. ej. fenobarbital)…»

    AEMPS, section 4.5 · Open on CIMA

  • Moderateinhibidores de la bomba de protonesclass named in the label
    «Los siguientes medicamentos pueden potenciar el efecto anticoagulante de acenocumarol : alopurinol, esteroides anabolizantes, andrógenos, agentes antiarrítmicos (p.ej. amiodarona, quinidina)…»

    AEMPS, section 4.5 · Open on CIMA

  • Moderateinhibidores de la proteasa del VIHclass named in the label
    «Los siguientes medicamentos pueden disminuir el efecto anticoagulante de acenocumarol : aminoglutetimida, antineoplásicos (azatioprina, 6-mercaptopurina), barbitúricos (p. ej. fenobarbital)…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateISRSclass named in the label
    «Los siguientes medicamentos pueden potenciar el efecto anticoagulante de acenocumarol : alopurinol, esteroides anabolizantes, andrógenos, agentes antiarrítmicos (p.ej. amiodarona, quinidina)…»

    AEMPS, section 4.5 · Open on CIMA

  • «Los siguientes medicamentos pueden potenciar el efecto anticoagulante de acenocumarol : alopurinol, esteroides anabolizantes, andrógenos, agentes antiarrítmicos (p.ej. amiodarona, quinidina)…»

    AEMPS, section 4.5 · Open on CIMA

From other drugs’ labels

  • «Anticoagulantes Warfarina, acenocumarol: Reducción de los niveles plasmáticos con riesgo de fallo terapéutico, reducción del efecto anticoagulante y necesidad de aumentar las dosis del tratamiento…»

    AEMPS, section 4.5 · Open on CIMA

  • «La vitamina K 1 antagoniza el efecto de los anticoagulantes derivados de la cumarina (como acenocumarol y warfarina).La coadministración de anticonvulsivantes puede afectar la acción de la vitamina K…»

    AEMPS, section 4.5 · Open on CIMA

  • «Debido a que la vinpocetina disminuye la agregación plaquetaria, debe evitarse en pacientes en tratamiento con medicamentos antiagregantes o anticoagulantes. Por lo tanto, debe evitarse la…»

    AEMPS, section 4.5 · Open on CIMA

  • «- Anticoagulantes orales , como dicumarol, acenocumarol, warfarina: posible aumento del riesgo de sangrado; la administración concomitante con grandes dosis de vitamina E (300 mg al día o mayores)…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateAmoxicillin
    «Anticoagulantes orales: Los anticoagulantes orales y las penicilinas se han usado ampliamente en la práctica clínica sin que se hayan notificado interacciones. Sin embargo, en la literatura hay casos…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateAzathioprine
    «Se ha notificado la inhibición del efecto anticoagulante de la warfarina y del acenocumarol al administrarse conjuntamente con azatioprina; por consiguiente, pueden ser necesarias dosis más altas del…»

    AEMPS, section 4.5 · Open on CIMA

  • «Antagonistas de la vitamina K: Se aconseja una monitorización frecuente del INR durante y justo después de la administración concomitante de ciprofloxacino con un antagonista de la vitamina K (p. ej…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateClindamycin
    «Se han notificado casos de incremento en los valores de las pruebas de coagulación (TP/INR) y/o sangrado, en pacientes que estaban siendo tratados concomitantemente con clindamicina y un antagonista…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateErythromycin
    «La eritromicina es un inhibidor de la CYP3A4 y la proteína transportadora glucoproteína P. Es difícil predecir el alcance de la inhibición de los distintos sustratos del CYP3A4. Por lo tanto, no…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateGemfibrozil
    «Anticoagulantes concomitantes: Gemfibrozilo puede potenciar los efectos de los anticoagulantes antagonistas de la vitamina K tipo cumarina tales como warfarina, acenocumarol o femprocumon. La…»

    AEMPS, section 4.4 · Open on CIMA

Showing 40 of 68, heaviest first

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Frequently asked

What is Acenocoumarol used for?

Acenocoumarol is evaluated for the following indications with varying evidence strength: Mechanical heart valve (evidence tier A), Venous thromboembolism (evidence tier B), Atrial fibrillation (evidence tier B). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Acenocoumarol?

Common side effects of Acenocoumarol (≥ 1 in 100): Bleeding at various sites. See the Safety section for uncommon and serious reactions.

Is Acenocoumarol safe during pregnancy?

Contraindicated in pregnancy. Like other coumarin derivatives, acenocoumarol crosses the placenta and may cause birth defects (AEMPS ficha técnica, sections 4.3 and 4.6). Women of childbearing potential need effective contraception during treatment. If pregnancy is planned, the anticoagulant is changed in advance together with the doctor who manages the anticoagulation.

Is Acenocoumarol compatible with breastfeeding?

Acenocoumarol passes into breast milk in very small amounts that, from the limited data available, do not harm the baby (AEMPS ficha técnica, section 4.6). The decision to breastfeed is made individually, and the baby's clotting and vitamin K are sometimes checked first. The ficha advises giving the baby 1 mg of vitamin K1 a week as prevention and keeping the mother's INR within the target range.

Who should not take Acenocoumarol?

Acenocoumarol is contraindicated in: Hypersensitivity to acenocoumarol or other coumarin derivatives; Pregnancy; Patients unable to follow treatment and INR monitoring without supervision; Bleeding tendency, clotting disorders, platelets below 50×10⁹/L; Recent or planned surgery on the central nervous system or eyes, extensive traumatic procedures. Full list in the Safety section.

Official sources

Direct links to regulator labels. Open in a new tab.

How to cite

Vancouver

Acenocoumarol [Internet]. Evigrade; 2026 [updated 2026 Oct 27]. Available from: https://www.evigrade.com/en/drugs/acenocoumarol

APA 7

Evigrade. (2026, October 27). Acenocoumarol. https://www.evigrade.com/en/drugs/acenocoumarol

Other drugs in this group

Acetylsalicylic acid, Apixaban, Clopidogrel, Dabigatran, Enoxaparin sodium, Rivaroxaban, Edoxaban, Nattokinase (serine protease from fermented soybean natto, Bacillus subtilis var. natto)